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ABSTRACT 
 
Improved continuous glucose monitoring devices have the potential to increase 
patient compliance and improve the management of diabetes.  One type of sensing 
chemistry that has been recognized as having significant amount of potential is based on 
the protein, Concanavalin A.   However, to date, this assay has continually shown 
problems with sensitivity, stability, and reversibility in free solution.  This work uses 
rational design to generate a new version of the competitive binding assay that can allow 
for its full potential to be shown.   
The first part of this work uses a glycosylated dendrimer as the competing ligand 
in the assay.  This assay is optimized with regards to its fluorescence response and 
encapsulated within microporated microspheres to allow for the glucose-dependent 
aggregative response to occur.  The exact mechanism of this assay was explored, and the 
stability issues were identified to be a direct result of the electrostatic interactions and 
multivalent presentation of sugar residues. 
The second part of this work generated a model for the unique recognition and 
transduction mechanisms of the ConA-based assay, in an attempt to generate maps to 
identify desirable qualities to generate an optimized assay.  This model was validated 
with experimental data, and used to optimize a ConA-based assay to track glucose 
concentrations with anisotropy.  They were also used to explain the problems with 
previous ConA-based approaches.  The core trimannose of N-linked glycans was 
recognized as a high-affinity ligand that achieved the required affinities without leading 
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to the aggregation that has caused previous assays to fail.  A smartly-designed 
fluorescent ligand was generated based on this core trimannose to achieve the desired 
qualities as defined by the previous models, and it was used in a ConA-based assay to 
track glucose concentrations with anisotropy and Fӧrster Resonance Energy Transfer 
(FRET).  Finally, in an attempt to generate a cost-effective smartly-designed fluorescent 
ligand that could be encapsulated with a size exclusion membrane, the glycated fraction 
of ovalbumin was fluorescently labeled and used in a ConA-based assay.  This work 
proves that the smartly-designed fluorescent ligand concept can overcome the problems 
of previous ConA-based assays, and such an assay is expected to be capable of 
translation to practical applications. 
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CHAPTER I 
INTRODUCTION AND BACKGROUND
*
 
 
Glucose Metabolism 
Glucose is a simple 6-carbon sugar that is used as an energy source for most 
organisms.
1
  Glucose is an ideal reducing monosaccharide for this role due to its lower 
tendency to react non-enzymatically with the amino groups that are commonly found on 
proteins.  In solution, glucose primarily exists in cyclic form with less than 0.1% of the 
glucose molecules in open chain form.  Other monosaccharides exist in the acyclic form 
at a higher percentage and would lead to increased levels of glycation.  Reducing 
monosaccharides either have an aldehyde or are capable of forming an aldehyde in the 
open chain.  These aldehydes can form Schiff-bases with primary amines and then 
rearrange to form permanent, advanced glycated end-products (AGEs).  AGEs 
irreversibly change the properties of the protein and are the source of the secondary 
complications associated with the widely-known disease Diabetes Mellitus.
2
   
In a healthy individual, the blood glucose concentration is held relatively 
constant even under high loads and demands of glucose.  These steady-state 
concentrations are at levels that are high enough to meet the continuous demand of the 
tissue without being in excess.  The hormones insulin and glucagon constantly provide 
                                                 
*
 Part of this chapter is reprinted from B. M. Cummins, J. Lim, E. E. Simanek et al., “Encapsulation of a 
concanavalin A/dendrimer glucose sensing assay within microporated poly (ethylene glycol) 
microspheres,” Biomedical Optics Express, 2(5), 1243-1257 (2011) with kind permission of OSA, 
 2 
 
feedback control to maintain normal levels.
1,3
  Insulin is released in hyperglycemia 
conditions, and glucagon is released in hypoglycemia conditions.    
Insulin is a 5.8 kDa peptide hormone that is produced by the beta cells of the 
pancreas and stored in secretory vesicles that respond to glucose concentrations.  The 
body responds to high glucose concentrations by releasing insulin to stimulate the cells 
in the liver, muscles and fat to absorb glucose.  This absorbed glucose is then converted 
to the energy storage unit known as glycogen.  A single glycogen molecule can store 
thousands of glucose molecules.  While each glucose molecule has a reducing terminus 
capable of forming AGEs with an amine-bearing protein, once it is stored in the 
glycogen molecule, it does not.
1,3
   
Glucagon is a 3.5 kDa peptide hormone that is generated in the alpha cells of the 
pancreas.  In hypoglycemia conditions, glucagon binds to the glucagon receptors of 
hepatocytes, stimulating the conversion of stored glycogen into individual glucose 
molecules to be released to meet the energy demand of the body.
3
   
 
Overview of Diabetes Mellitus 
Diabetes is a disease where the body is unable to enact the normal feedback 
mechanism to convert excess glucose into glycogen, and it is characterized by elevated 
blood glucose concentrations.
4-6
  As a result, the patient is more likely to form AGEs 
which can cause complications in tissues/organs with relatively long-lived proteins/cells.  
There are two primary types of diabetes.  Types 1 diabetes is an autoimmune disorder 
that results in the destruction of the beta cells in the pancreas and is often referred to as 
 3 
 
juvenile diabetes or insulin-dependent diabetes.  This type results in an absolute insulin 
deficiency where insulin is no longer released at concentrations that can help control the 
concentrations of glucose.
7-9
  Type 2 diabetes is characterized by insulin resistance due 
to lifestyle and genetic factors.  Lifestyle factors that increase the risk of developing 
Type 2 diabetes include obesity, lack of physical activity, poor diet, and stress.
10,11
  Of 
the total number of diabetes cases, approximately 10% have Type 1 and 90% have Type 
2.
12
   
This disease is currently at epidemic proportions in the United States and 
worldwide.  In the United States, approximately 25.8 million people have diabetes.
13
  
Worldwide, the World Health Organization (WHO) estimates there to be 346 million 
people with the disease, where more than 80% of the people with diabetes live in low- 
and middle-income countries.
14,15
  In 2012, the direct and indirect expenditures 
associated with diabetes totaled 548 billion U.S. dollars.
12
  These numbers are expected 
to continue to rise.  Half of the adult population in the U.S. is expected to have pre-
diabetes or diabetes in 2020.
16
  By the year 2035, there are estimates that diabetes will 
affect 592 million people worldwide.
12
   
The original diagnosis of diabetes can be made with several different methods: 
the A1C test, the fasting plasma glucose (FPG) test, and the oral glucose tolerance test 
(OGTT).  The A1C value is effectively the percentage of the hemoglobin that is 
glycated.  Since hemoglobin is a relatively long-lived protein, it can give an average of 
the blood glucose values over the last month.  The FPG measures the blood glucose 
concentrations of an individual that hasn‟t had any caloric intake for 8 hours.  The 
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OGTT is a two-hour test that tests how your body responds to a certain amount of 
glucose.  Healthy individuals display an A1C value of less than 5.7%, a FPG of less than 
100 mg/dL, and an OGTT of less than 140 mg/dL.  Diabetes is often diagnosed with an 
A1C value of higher than 6.5%, FPG of higher than 126 mg/dL, and an OGTT of higher 
than 200 mg/dL.  Prediabetes is diagnosed with test results that are in between those 
identified by diabetes and normal. It has been shown that the onset of diabetes can be 
delayed if the proper lifestyle changes are made.
4
         
 
 
Figure 1: Increase in the risk of complications according to the mean blood sugar.  This 
exponential curve was fit to the data from the 1993 trial. 
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In 1993, the Diabetes Control and Complications Trial published 10 years of data 
from multiple centers that showed improved glycemic control (maintaining blood 
glucose values within normal ranges) decreased secondary complications associated with 
diabetes.
17
  Figure 1 shows the risk in complications as a function of the patient‟s mean 
blood sugar as a fitted exponential to the data from the 1993 trial.  Typical mean blood 
sugar values that are seen for normal and uncontrolled diabetes are shown, as well as the 
goal for diabetes management.  
This trial also showed that the strict management of glucose also increased the 
risk of time spent in hypoglycemia.
17
  Hypoglycemia is the result of delivering too much 
insulin for the glucose levels present in the system, and it can result in coma and even 
death.  The high residual insulin concentrations continue to convert glucose into 
glycogen even though the amount of glucose in the blood is dangerously low.   
Therefore, the management of blood glucose concentrations is a balance between 
minimizing the average blood glucose concentrations and avoiding hypoglycemic 
events.    The target A1C value for diabetic management (7%) is typically higher than 
what is normal for a healthy individual (less than 5.6%).
4
  Upon diagnosis, physicians 
typically instruct interventions such as exercise, diet, delivery of exogenous insulin, and 
medication.  There are many different types of insulin that can be delivered: rapid-
acting, short-acting, intermediate-acting, and long-acting.
18
  There are as many different 
medications that try to improve the response to insulin or the production of insulin in 
various ways.
19
  Because of the numerous possibilities for management plans, it is 
imperative that the patient meets with his/her physician and follows the management 
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plan that is chosen.  Each management plan depends on the blood glucose information; 
however some plans require more frequent information than others.  For those plans that 
require current information, the patients are instructed to perform frequent blood glucose 
measurements.
4
  
 
Glucose Monitoring 
Commercial Glucose Sensors 
The blood glucose meter is the primary tool to perform these measurements, and 
it is widely considered the most successful commercial biosensor to date.
20
  Briefly, the 
device requires a drop of blood to be applied to an enzyme-coated paper strip that is then 
inserted in a handheld device to be measured.  The enzymes on the paper strip consume 
the glucose, converting it into byproducts that are typically measured electrochemically.  
The device uses an algorithm to convert this signal into an expected blood glucose 
concentration, and these readings typically show an error that is less than 20%.  Possible 
sources of increased error include the denaturation of the enzymes on the paper strip, 
inadequate blood volumes, and variations due to temperature.
21
   
Physicians typically instruct patients that use insulin to make 5-7 measurements 
per day (before and after meals) to get a true picture of the daily profile and allow one to 
minimize the time outside of normal levels.  However, the majority of patients display 
low compliance to this instructed frequency of measurement – which has been attributed 
to inconvenience (pain, time, etc.).  In fact, 60% of the patients that rely on insulin 
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average less than a single measurement per day.  That number increases to 95% for 
patients who do not use insulin.
22
   
Continuous glucose monitoring (CGM) has been identified as a technique that 
can improve diabetes management by placing less of a demand on the patient and giving 
the user more information.
23
 The current CGM devices on the market are marketed for 
trending information, and they display the current glucose levels and historical trends on 
the monitor.  They also notify the patient before they reach levels previously defined 
limits (low and high).  As a result, this technique has been shown to result in fewer highs 
and fewer lows, improving diabetes management.
24,25
  These current CGM sensors are 
based on a similar electrochemical-enzymatic approach to the paper strips, and this 
chemistry is placed on the tip of an electrode in a diffusion-limiting matrix.  This sensor 
is placed just underneath the skin in the interstitial fluid, and the matrix allows glucose, 
oxygen, and other small molecules to reach the sensing chemistry.  The enzymatic 
chemistry consumes glucose, and the byproducts undergo redox reactions with an 
electrode to generate a current that is glucose-dependent.
26
     
The primary problem facing current CGM devices is the foreign body 
response.
27-29
  Because the reorganization of the tissue changes the absolute and relative 
glucose and oxygen transport, several calibrations are required each day to maintain 
accurate glucose predictions.  Eventually, the limited transport prevents the sensors from 
displaying sufficient accuracy and requires replacement after 3-7 days.  It is important to 
note that the sensors continue to work once they are removed and cleaned, indicating 
that it is truly a transport problem.
30
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Research towards Improved Glucose Sensors 
An extensive amount of research is being done to improve the accuracy and 
lifetime of CGM devices.  One approach is to minimize the foreign body response to the 
percutaneous sensor for current CGM devices.  Modeling has been performed to identify 
the specific characteristics of this foreign body response that disrupt the sensor 
predictions.  The changes in transport are not only due to the lag time due to the 
increased diffusion barrier, but they are also due to the increased consumption by the 
metabolically active cells in the area.
31
  Research groups have devised numerous 
strategies to minimize this response, including the release of drugs and the design of the 
surface of the membrane.
32-34
  It is also possible that this response can be minimized by 
fully-implanting the device.
35
     
In addition to the electrochemical-enzymatic sensing scheme, there are many 
alternative approaches that have been explored in research labs.  Techniques based on 
microdialysis, near-infrared (NIR) absorption, Raman spectroscopy, and polarimetry all 
show considerable potential, and groups are currently pursuing them in research labs.
36
  
One particularly attractive sensing approach is a fluorescent affinity-based assay, in 
which the sensor employs a glucose-receptor for the specificity.
37,38
  Instead of 
measuring the rate of consumption with an electrode, the equilibrium binding can be 
interrogated with an optode.  This type of approach has recently received significant 
amount of interest by major medical device companies.  Becton Dickinson has pursued a 
fluorescent affinity-based sensor based on the glucose-binding protein for many years.
39
  
In addition, Medtronic has recently acquired the fluorescent competitive binding 
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affinity-based technology from PreciSense.
40
  In 2012, they were awarded $20 million 
from the Juvenile Diabetes Research Foundation (JDRF) to combine this approach with 
their traditional CGM approach to create an orthogonally redundant glucose sensor in an 
attempt to improve the accuracy and stability of the sensor.  This recent activity indicates 
that large medical device companies recognize the many advantages that optical affinity-
based chemistries can offer to generate an improved CGM device. 
 
Outlook 
Current glucose sensing strategies already offer the user information that can 
allow for improved diabetes management, but they place a significant burden on the user 
and display low patient compliance.  This low compliance could be due to the 
requirements placed on the user to perform either the measurement or the intervention 
components required for proper management. For both of these issues, an improved 
CGM device has the potential of improving patient compliance.  A CGM device that 
requires fewer calibrations and fewer replacements could minimize the requirements 
placed on the user to collect blood glucose concentration data.  In addition, an improved 
CGM device could minimize the burden on the user by allowing for the realization of the 
artificial pancreas.   
The artificial pancreas is a device that connects a CGM device with an insulin 
pump to continuously deliver the insulin required to keep the blood glucose 
concentrations within normal values.
41
  The delivery of insulin must be carefully 
administered; delivering too much can result in severe hypoglycemia.  To mitigate this 
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risk, this strategy has started to include a glucagon pump to allow the system to increase 
glucose levels as well.
42
  This type of system could function for long periods of time 
without input by the user.  As a result, this concept requires accurate CGM readings for 
it to become a reality.  JDRF has identified the Artificial Pancreas Project to transform 
the lives of people with Type 1 diabetes.   In 2013, the top priority area of JDRF‟s 
Artificial Pancreas Project is the development of differentiated glucose sensing 
technologies to improve reliability and accuracy of continuous glucose monitors.   
 
Concanavalin A-Based Glucose Sensors 
One glucose sensing technology that has generated interest over the last three 
decades is the fluorescent affinity-based assay using Concanavalin A (ConA) as the 
receptor.  ConA is a c-type lectin that is a tetramer at physiological pH with a molecular 
weight of 104 kDa .  Lectins are a set of proteins that reversibly and non-enzymatically 
bind specific carbohydrates, and ConA binds glucose and mannose in the presence of 
certain divalent cations.
43,44
  Unlike proteins such as hexokinase and glucose-binding 
protein, ConA does not undergo a measurable conformational change upon its binding to 
glucose.
45,46
  Instead, ConA-based sensors typically employ a competing ligand and 
track the glucose concentration with the amount of competing ligand is bound to ConA.  
As the assay is exposed to increasing glucose concentrations, the amount of the 
competing ligand bound to ConA decreases, which can be transduced via 
fluorescence.
47-50
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Dr. Irwin Goldstein performed a significant amount of work with ConA in the 
1960s and 1970s that paved the way for much of the understanding of the lectin.
51-57
  His 
quantitation precipitation studies showed a significant percentage of the lectin fell out of 
solution when it was paired with certain various polysaccharides, such as dextrans and 
glycogens.  This precipitation was prevented to varying degrees with certain 
monosaccharides, and as a result he identified the requirements for a monosaccharide to 
bind to the primary binding site of ConA.  These have been coined as the “Goldstein 
Rules.”  Each monomeric subunit of ConA contains a single primary binding site 
capable of binding glucose and mannose monosaccharides with unmodified hydroxyls at 
positions C3, C4, and C6.
52,58,59
  Dextrans are polysaccharides of glucose and are 
primarily comprised of α-1,6 glycosidic linkages with branches formed by α-1,3 
linkages.
60
  Due to this branching, dextrans can have many non-reducing termini to 
which ConA can bind.  As a result, dextrans can display a higher affinity to ConA than 
their monomeric subunit D-glucose and this affinity increases for larger molecular 
weight dextrans.
61
 
The cell membrane displays certain glycoproteins to the external environment 
that can be recognized by ConA.
44
  Native, tetrameric ConA displays binding sites that 
are approximately 6.5 nm apart from one another and could potentially cluster the 
glycoproteins upon binding.  However, the biotoxicity of ConA has been extensively 
studied, and has been shown to pose little to no adverse health risk in use for in vivo 
sensing at low concentrations.
62
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As a result, ConA-based competitive binding assays have been developed as 
potential solutions for in vivo continuous glucose monitoring applications.  This was first 
introduced by Dr. Schultz, Dr. Mansouri, and Dr. Goldstein in 1982.
48
  In this work, 
ConA was paired with FITC-labeled dextran in a microdialysis membrane that was fit at 
the end of an optical fiber.  While the FITC-dextran was left free in solution, ConA was 
tethered to the inner wall of the membrane.  Glucose could equilibrate across the 
membrane, but FITC-dextran was large enough to be held inside. 
This significant potential of this scheme has led to many variations in the design 
of the fluorescent competing ligands, optical transduction mechanisms, and 
encapsulation techniques used with this assay.
47,49,63-69
  Fluorescence assays have been 
proposed to be encapsulated inside microspheres or fibers, embedded within the dermis, 
and optically interrogated from the surface of the skin.  However, to date, they have 
continued to display sub-optimal sensing performance when both assay components 
were left in free solution.   
Problems with irreversibility and precipitation in free solution have consistently 
been reported by research groups.   Specifically, Dr. Joseph Lakowicz‟s group stated that 
“the success of a glucose sensor using ConA as the glucose-binding protein depends on 
being able to eliminate agglutination.”70  In addition, Dr. Birch‟s group stated that “the 
main obstacle to developing this assay for in vivo use is the tendency for ConA 
complexes to precipitate after extended incubation periods, particularly at low glucose 
concentrations.”71 
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The objective of the work presented in this dissertation is to show the full 
potential of the fluorescent affinity-based assay using Concanavalin A (ConA) for 
continuous glucose monitoring applications. 
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CHAPTER II 
ASSAY BASED ON CONCANAVALIN A AND GLYCOSYLATED DENDRIMER
*
  
 
Introduction 
In an attempt to decrease the irreversible binding associated with the 
ConA/dextran system, our group has previously employed the use of glycosylated 
dendrimers as the competing ligand.
72
 Dendrimers are tree-shaped, globular 
macromolecules that have been explored for potential uses in chemotherapeutics,
73,74
 
anti-viral pharmaceuticals,
75-79
 and scaffolds for tissue repair due to their 
biocompatibility.
80,81
  By adjusting the size and altering the functional end-groups of the 
dendrimers, the effective diameter, molecular weight, and hydrophilicity can be 
varied.
82-84
  Using specifically tailored glycosylated dendrimers that can bind to ConA, 
our group has generated a competitive binding assay that has been shown to be sensitive 
to glucose concentrations.  The assay components have been shown to remain functional 
for several days after being held at body temperature (37 °C) when they were separate 
and paired together.
85
  A schematic of the ConA/glycosylated dendrimer glucose 
response is shown in Figure 2.   
                                                 
*
 Part of this chapter is reprinted from B. M. Cummins, J. Lim, E. E. Simanek et al., “Encapsulation of a 
concanavalin A/dendrimer glucose sensing assay within microporated poly (ethylene glycol) 
microspheres,” Biomedical Optics Express, 2(5), 1243-1257 (2011) with kind permission of OSA, 
Copyright 2014 by The Optical Society; and from B. M. Cummins, J. Lim, E. E. Simanek et al., 
"Understanding the mechanism and optimizing a competitive binding fluorescent glucose sensor." 7906. 
(2011) with kind permission of SPIE, Copyright 2014.   
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This chapter further explores the ConA-based glucose sensing assay that employs 
these glycosylated dendrimers.  A set of glycosylated dendrimers with unique 
characteristics were paired with ConA in assays to determine which assay maximized 
the fluorescence response to physiologically relevant glucose concentrations.  One of 
these assays was encapsulated using a microporated microsphere approach to allow 
glucose diffusion to occur and the assay to respond.  The stability issues that have 
continued to plague this type of assay in free solution were then explored further.   
 
 
Figure 2: Schematic representation of the aggregative nature of the ConA/glycosylated 
dendrimer assay. In (a) low glucose concentrations, the assay emits lower fluorescence 
than (B) in high glucose concentrations. 
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Optimization Studies 
Traditional ConA-based sensors typically shown a ~30% increase in the 
fluorescence of the donor fluorophore across physiological glucose concentrations in 
free solution.
47,86,87
  Previous versions of this ConA/glycosylated dendrimer assay have 
shown significantly larger changes across these same glucose concentrations.
67,88
  
However, while this assay was originally engineered to display a typical Fӧrster 
Resonance Energy Transfer (FRET) response, it did not show such a response.  In a 
competitive binding assay that uses FRET to transduce the binding, low concentrations 
of the analyte of interest (glucose) should allow for a large amount of binding to occur 
between the fluorescent receptor and the fluorescent ligand.  This binding can allow for 
energy transfer to occur, decreasing the steady-state fluorescence intensity from the 
donor.  Upon the addition of the analyte of interest, there should be a decrease in the 
amount of fluorescent receptor that is bound to the fluorescent ligand, and the donor 
fluorescence should increase. For the work with the glycosylated dendrimer, the opposite 
response was seen.  The fluorophore that should have acted as the acceptor increased 
with the addition of the glucose.   
This ConA/glycosylated dendrimer assay also generated a fluorescence response 
to glucose concentrations when the glycosylated dendrimer was unlabeled.
89
  This 
suggested that part of the fluorescence response stemmed from the glucose-dependent 
aggregation of the Alexa Fluor 647 labeled ConA (AF647-ConA).  This aggregation 
could decrease the fluorescence through several pathways, including: (1) homo-FRET 
(where the fluorophore on ConA could transfer energy to an unexcited fluorophore on a 
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neighboring ConA), (2) increased scattering of the solution (shielding), and (3) the 
fluorescent material falling out of solution due to precipitation.     
To examine whether the dynamic range of this assay based on AF647-ConA could be 
extended even further by combining the aggregation effects with energy transfer, a set of 
different glycosylated dendrimers were designed to be capable of undergoing energy 
transfer with the AF647 fluorophore.  Instead of being labeled with the donor-
fluorophore of the FRET-assay, these dendrimers were labeled with chromophores that 
could serve as the acceptor-fluorophore with AF647-ConA.  To this end, a set of 
glycosylated dendrimers were synthesized and provided by Dr. Eric Simanek and used 
as received.  Generation two (G2) triazine dendrimers (MW ~9kDa & ~1.5 nm diameter) 
were provided with 12 glucose groups and 12 amine groups in unlabeled, QSY-21-
labeled, and Alexa Fluor 750 (AF750)  labeled versions.  Generation four (G4) triazine 
dendrimers (MW ~36 kDa & ~2.5 nm diameter) were provided with 48 glucose groups 
and 48 amine groups in unlabeled, QSY-21-labeled, and AF750-labeled versions.  The 
degree of labeling was expected to be 1 label per glycosylated dendrimer.  Accordingly, 
the expected number of amines for the labeled versions was one less than the unlabeled 
version of the same size.   
The QSY-21 label is a non-fluorescent diarylrhodamine chromophore that can 
serve as a FRET-acceptor with AF 647.  The donor/acceptor FRET pair has an expected 
Fӧrster radius of 6.9 nm.  The AF 750 label is a fluorophore with similar fluorescent 
properties to Cy7.  The Alexa Fluor set of dyes are typically sulfonated versions of other 
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dyes – resulting in a fluorophore that is brighter, more stable, and less sensitive to pH.  
Several of the key properties of these fluorophores are listed in Table 1. 
 
Table 1: Properties of the fluorophores used in the ConA/glycosylated dendrimer assay. 
Fluorophores 
Maximum 
Absorbance (nm) 
Extinction 
Coefficient (cm
-1
M
-1
) 
Quantum 
Yield 
AF 647 650 239,000 0.33 
AF 750 749 240,000 0.12 
QSY-21 661 90,000 0 
 
 
   ConA was fluorescently labeled with AF647 via the following method.  
Briefly, 10 mg of ConA was dissolved in 1 mL of 0.1 M sodium bicarbonate buffer (pH 
~8.3) and 1 mg of AF647 succinimidyl ester was added to 100 µL DMSO. The dye 
solution was then added drop-wise to the protein solution while it was being stirred, and 
allowed to react for one hour in the dark.
90
 The solution was then loaded onto a G75 
Sephadex column that had been pre-swelled and equilibrated with TRIS buffer (with the 
required divalent cations).  Inactive ConA and free AF647 dye eluted from the column 
with TRIS, and the active, AF647-ConA was eluted with a 200 mg/mL glucose solution 
in TRIS. This fraction was collected and dialyzed against TRIS buffer to remove the 
glucose in the solution. After centrifugation, the concentration and labeling ratio were 
then determined by measuring the absorption spectra. These measurements were 
performed by UV-VIS spectrometry indicating a labeling ratio of 4.7 dye molecules per 
ConA tetramer. This sample was used for subsequent studies.  Samples that were not to 
be used immediately were added to centrifuge tubes and frozen for a later date.  The 
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comparison of excitation and emission fluorescent spectra of AF647 with QSY-21 and 
AF647 with AF 750 are shown in Figure 3.   
 
 
Figure 3: Excitation/emission properties of the chromophores within the 
ConA/glycosylated dendrimer optimization studies. (A) AF647 and QSY-21, and (B) 
AF647 and AF 750. 
 
 
To be able to quickly judge the effectiveness of these ConA/glycosylated 
dendrimer assays, fluorescence measurements were performed on a microplate reader.  
Each ConA and glycosylated dendrimer combination was loaded to the microplate at a 
set of different assay configurations with a final volume of 300 µL.  These six assay 
configurations are shown in Table 2.  Each of these configurations were loaded in 
triplicate in the absence and presence of 500 mg/dL glucose concentrations, allowed at 
least 15 minutes to equilibrate prior to measurements. 
 
 20 
 
Table 2: Assay configurations tested for each ConA/glycosylated dendrimer assay. 
Assay Configuration [ConA] (nM) [Dendrimer] (nM) 
1 500 500 
2 250 250 
3 500 250 
4 250 500 
5 1000 500 
6 1000 250 
 
 
Measurements were performed on the monochromator-based Tecan microplate 
reader from a top-reading, fluorescence approach.  The excitation wavelength was set to 
620 nm with a bandwidth of 10 nm.  The fluorescence emission was scanned from 650 
nm to 820 nm in 5 nm increments.  This emission had a bandwidth of 20 nm.  The gain 
was set to 94, and the integration time was 20 µs.  The z-position was 20126 µm.   The 
relative increase in the peak of AF647-ConA‟s fluorescence from 0 mg/dL glucose to 
500 mg/dL glucose was determined and shown in Figure 4.  The absolute increase 
(counts) in the peak of AF647-ConA‟s fluorescence from 0 mg/dL glucose to 500 mg/dL 
glucose was determined and shown in Figure 5.  Each well had the same experimental 
set up, allowing the absolute counts to be comparable.  The figure of merit was 
determined to be the product of the absolute increase and the relative increase, and this 
value is shown in Figure 6.  The absolute increase was included in the figure of merit 
because the signal-to-noise associated with fluorescence measurements is proportional to 
the square root of the number of counts measured (Poisson Distribution).   
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Figure 4: Relative increase in the peak of AF647-ConA‟s fluorescence from 0 mg/dL 
glucose to 500 mg/dL glucose for each assay configuration.  
 
 
The relative changes in Figure 4 show that the largest relative changes are 
typically associated with the lowest initial AF647-ConA concentrations.  In addition, 
higher changes were typically seen when the ConA concentration was either equal to or 
lower than the glycosylated dendrimer concentrations.  The QSY-21 and unlabeled 
versions of the G4 dendrimer showed higher responses than for its G2 counterparts, but 
the opposite is true for the AF750-labeled version.  The QSY-21 labeled dendrimers 
showed mixed results when compared with the unlabeled dendrimers.  However, the 
AF750-labeled dendrimers were better than the unlabeled versions of both G2 and G4.  
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The highest responses were with the AF750-labeled G2 glycosylated dendrimer.  It is 
also important to note that each configuration with the G2-NH2 dendrimer showed small 
changes across physiologically relevant glucose concentrations.  This is different than 
what has been seen in cuvette based studies. 
 
 
Figure 5: Absolute increase (counts) in the peak of AF647-ConA‟s fluorescence from 0 
mg/dL glucose to 500 mg/dL glucose. 
 
 
For most cases, the absolute changes in Figure 5 seem to increase the most in 
assays that showed higher concentrations of AF647-ConA.  The highest ConA 
concentrations (1 µM) showed a higher change in absolute fluorescence counts than the 
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other samples.  These samples have the most AF647 in the solution, and can allow for 
large changes in absolute count even with smaller ratiometric responses.  Again, in each 
assay configuration the G2-AF750 glycosylated dendrimer showed the highest 
responses.  
 
 
Figure 6: Figure of merit (ratio*absolute) increase for each assay configuration. 
 
 
According to the figure of merits (Figure 6), the optimized assay configuration is 
composed of 1 µM AF647-ConA with 500 nM AF750-G2 dendrimer.  The G2 AF 750 
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dendrimer‟s figure of merit was consistently better than the unlabeled G2 dendrimer in 
each assay configuration.  This could indicate that the additional pathway of energy 
transfer can further increase the dynamics of the assay.  However, the G4 AF 750 
dendrimer showed similar responses to the unlabeled G4 dendrimer.  This could be due 
to the difference in diameters between G2 and G4 dendrimers, where the smaller 
dendrimers display a higher FRET-efficiency.  The dendrimers labeled with QSY-21 
should show a similar trend as the dendrimers labeled with AF750.  However, both the 
G2 and G4 versions of the QSY-21 labeled dendrimers showed similar responses to the 
unlabeled versions.     
A full study of the glucose response of the assay of 1 µM AF647-ConA with 500 
nM AF750-G2 dendrimer was run in a similar configuration as to the previous study.  
Glucose concentrations ranged from 0 mg/dL glucose to 1000 mg/dL.  This response is 
shown in Figure 7.  This response shows the highest change in response across 
physiological glucose concentrations, increasing its fluorescence by ~250% from 0 
mg/dL to 400 mg/dL. 
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Figure 7: Glucose response of the 1 µM AF647-ConA and  
500 nM AF750-G2 dendrimer assay. 
 
 
In summary, the systematic evaluation of the various glycosylated dendrimers 
and assay configurations generated a specific fluorescence assay that displays a high 
sensitivity to physiological glucose concentrations.  However, the introduction of a 
FRET acceptor to the glycosylated dendrimer should have increased the number of 
quenching/transfer pathways possible for the AF647 fluorophore on ConA in each assay.  
While that was seen for the AF 750-G2 vs. the unlabeled G2, it was not consistently seen 
for any other dendrimer.  This is probably due to different complex binding interactions 
between ConA and the various dendrimers, especially upon aggregation.  Observing 
significant variations like this could indicate problems with stability and repeatability 
like previous versions of this assay.  The aggregative interaction between ConA and the 
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glycosylated dendrimer appears to be complex, and it calls for a further exploration to 
assure a stable, optimized assay.  One potential method that was explored in an attempt 
to stabilize this assay was encapsulating it in microspheres. 
 
Encapsulation within Microporated Microspheres 
For functioning aggregative assays to be translated from cuvettes and microplate 
wells to implantable sensors, specifically tailored encapsulation methods which maintain 
the chemistry‟s binding kinetics must be employed. Requirements for such a strategy 
must prevent the leaching of assay components while allowing for the diffusion of the 
targeted analyte and response of the sensing chemistry to the analyte. Much work in the 
field of encapsulation has been focused on the extension of drug delivery profiles. 
Concepts such as polymeric microspheres and layer-by-layer (LbL) approaches have 
been used and reported.
91-96
 These microencapsulation techniques have begun to be 
altered for general sensing purposes in attempt to meet the aforementioned 
requirements.
97
 For example, several groups have loaded sacrificial spherical templates 
(i.e. melamine formaldehyde and calcium carbonate) with proteins and sensing 
chemistry that can then be exposed to alternating layers of poly-electrolytes which coat 
the template.
98-100
 These cores can then be dissolved freeing the chemistry within the 
micron-sized LbL capsule that can then serve as a semi-permeable membrane for 
sensing purposes. Advantages of this technique include the fine level of control for the 
mesh size of the capsule and the high synthetic reproducibility. However, future work 
must be done to minimize the effects of electrostatic binding of the sensing chemistry to 
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the charged interior wall of the capsule.
101
 Additionally, groups have embedded sensing 
chemistries within a dense matrix in an attempt to maintain long-term functionality. 
Poly-(ethylene glycol) (PEG) has been employed in this manner due to its proven 
biocompatibility and hydrophilic nature.
102
 Microspheres can be created using PEG by 
crosslinking the individual chains via thermo-chemical or photo-chemical initiation, 
resulting in a mesh of PEG chains in which chemistry can be embedded. The effective 
pore size of this mesh can be altered by varying the average molecular weight of the 
PEG and/or changing the water content within the precursor solution prior to 
crosslinking.
103,104
 With these variations, the mesh size for PEG can be tailored to be 
suitable for sensing purposes. However, the sensing response of assays embedded within 
this mesh has been limited in its reversibility due to the consistent mesh within these 
spheres without attachment of the assay to the polymeric backbone.
105
 
Until now, the successful encapsulation of the ConA/glycosylated dendrimer 
sensing assay has not been reported. Previously, our group has proposed and presented 
an encapsulation strategy combining a water-in-oil emulsion technique with the addition 
of sugar crystals to the precursor PEG solution to form assay-filled pores within the 
hydrogel matrix of the microspheres. This microporation technique was shown to be 
functional with the ConA/Dextran glucose sensitive assay – displaying a reversible 
response over several days.
105
 Since microporated PEG spheres allowed competitive 
binding within the larger pores while providing for diffusion of smaller analytes due to 
the selectively permeable mesh, it was believed that similar biocompatible microporated 
microspheres may be candidates for housing the aggregative ConA/glycosylated 
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dendrimer sensing assay. Work presented here explores the effectiveness of this 
technique in encapsulating the sensing chemistry with respect to its dynamic range, 
sensitivity, and reversibility.  The assay that was encapsulated was the AF647-ConA and 
unlabeled G2-NH2 glycosylated dendrimer.   
 
Synthesis of Loaded Microspheres 
Two groups of microspheres, hereafter called microporated-PEG and PEG-50, 
were created to display the functionality of the microporated microspheres. PEG-50 
spheres are created with 50% water and 50% PEG, and microporated microspheres are 
created with pores within a 100% PEG solution. For comparison, schematic renditions of 
these are displayed in Figure 8 as well as that of 100% PEG solution. PEG-50 spheres 
have shown to be effective in allowing the assay to respond with limited reversibility 
while PEG-100 spheres have been shown to have limited response but high reversibility. 
Therefore, the microporation technique aims to capture the advantages of both by 
creating larger assay-filled pores within the tighter mesh of the PEG-100 spheres. 
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Figure 8: Schematic representation of the mesh/pore sizes of the various spheres 
described: (A) PEG50 spheres (B) PEG100 spheres and (C) Microporated spheres. 
  
 
The spheres were synthesized in the following way using AF647-ConA and G2-
Dendrimer stock solutions of 1 mg/mL.  To create the porogen for the microporated PEG 
microspheres, 200 µL of AF647-ConA stock solution, 100 µL of G2-Dendrimer stock 
solution, 300 µL of PBS, and 20 mg of mannitol were added together. This precursor 
solution was mixed well, and then lyophilized overnight. In order to make the precursor 
polymeric solution for the microporation technique, 10 mg of the lyophilized sample was 
added to 1 mL PEG-DA (MW 575) and 10 µL Darocur. This solution was stirred to 
break up the lyophilized crystals into smaller particles. To make the polymeric precursor 
for the PEG-50 microspheres, 500 µL PEG-DA (MW 575), 100 µL ConA, 50 µL G2 
Dendrimer, 350 µL TRIS buffer, and 10 µL Darocur were added together and mixed 
well. 
A water-in-oil emulsion technique was implemented by adding 50 mL of light 
mineral oil to a 100 mL beaker. This solution was stirred via a magnetic stir plate, 
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rotating at approximately 500 rpm. Under these conditions, the polymeric precursor was 
pipette into the beaker and allowed to spin for 15 seconds to create a fairly homogenous 
set of spheres. An ultraviolet light source (EFOS Ultracure 100SS Plus) at a wavelength 
of 365 nm was shone incident upon the beaker from a probe at 20 W/cm2 for 2.5 
seconds to sufficiently cause the cross-linking via free-radical photo-initiation. Spheres 
were removed from the oil bath and vigorously rinsed with TRIS buffer via several 
buffer exchanges, and then added to a final solution of TRIS buffer. Spheres were stored 
at 4  C after synthesis. 
 
Characterization of Loaded Microspheres 
To examine the average size of these particles, a bright-field microscopy 
technique was performed using a Leica DMLM microscope by adding a small volume of 
spheres on the surface of a microscope slide. To calculate the average diameter for each 
group of microspheres, ten images were captured by randomly translating the x-y 
motorized stage and focusing on the spheres within the image plane via a 10x objective. 
The diameters were calculated for each in-focus sphere that was taken, and the average 
diameter and standard deviation for each set was found. 
The poration within the PEG microspheres was examined through the use of a 
confocal fluorescence microscope by taking slices of the collected fluorescence through 
the depth of the sphere. This was performed using a Leica TCS SP5 Confocal 
Microscope. For these experiments, a HeNe 632.8 nm laser was used at 4.5 mW with a 
73.7 µm pinhole and a 10x, 0.3 NA, dry objective. Images were taken without averaging 
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and the resulting Z-step size was 2.383 μm with a 512 x 512 pixel resolution for the 
frame. This procedure was performed for both groups of the synthesized microspheres. 
Since these microspheres were comprised of a hydrogel material that largely consists of 
water, the refractive index of these spheres was approximately 1.37.
106
 These spheres 
were immersed in TRIS buffer (n = 1.33) for confocal scans. Therefore, the shape of the 
sphere did not display a significant distortion of the image as the index was somewhat 
matched. 
Fluorescent measurements with regards to leaching were performed on a 
commercially available spectrofluorometer system (Make: Photon Technology 
International, Model: Model L-201M Source, MP-1 Sample Compartment, and Model 
814 Analog/Photon-Counting Photomultiplier Detector). In emission scan mode, the 
incident light was set to 633 nm and the emission monochromator was scanned from 650 
nm to 710 nm with 1 nm steps and 1 second integration times. Fluorescent 
measurements of the sensing spheres with regard to response and long-term reversibility 
were taken with a custom-designed 90 degree fluorescence optical set up (Figure 9).  
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Figure 9: Schematic representation of the optical set up for the fluorescence 
measurements of the microspheres. 
 
 
A cuvette holder held the micro-cuvette containing the sensing spheres, and a 5 
mW, HeNe 632.8 nm laser was made incident normal to its face. Due to the slight 
mismatch of refractive index between the spheres (1.37) and the buffer (1.33), there 
were multiple scattering events. Given the 1 cm path length of the cuvette, a 1 mm beam 
width, and scatter due to the packed spheres, the sampling volume is approximately 25 
µL. This corresponded to approximately 250 spheres within that sampling volume. At 90 
degrees, a Roper Scientific SpectraPro 150 spectrometer was placed with a fixed slit 
width, and a 650 nm long-pass, emission filter was used to eliminate stray laser light. 
The integration time of the system was 500 milliseconds to avoid saturation of the 
signal, and the grating had a blaze wavelength at 750 nm with 1200 grooves/mm. For 
collection purposes, the spectrometer was centered at 690 nm, collecting counts from 
647 nm to 727 nm. This was performed to further minimize saturating the detector with 
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scattered light from the source and in order to sufficiently measure the peak of the 
AF647 emission at approximately 670 nm. The fluorescent intensity value used in all 
subsequent data analysis was the maximum value of the fluorophore emission for each 
spectrum collected. 
For titration measurements, 500 µL of microporated microspheres were packed 
within a microcuvette and 2 mL of TRIS buffer were added. These microcuvettes were 
used to minimize the amount of spheres used. Highly concentrated, low volume aliquots 
of glucose were then added to the cuvette to make the surrounding solution increase in 
glucose concentration. This addition was performed without perturbing the settled 
spheres to assure adequate comparison. Sufficient time was given to allow for the 
diffusion of varying glucose concentrations into the spheres and for the response of the 
assay to achieve steady state. Three runs were performed for the microporated spheres 
and triplicate data was recorded for each run. The refractive index change between 0 
mg/dL and 6000 mg/dL glucose levels have been shown to increase from 1.333 to 
1.34.
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 As the physiological glucose concentration are an order of magnitude less than 
this step change, the change in refractive index should be negligible when compared to 
the fluorescent response from the competitive binding chemistry. 
In addition, the titration was performed on free assay in solution. A sensing assay 
was formulated in an attempt to mimic those concentrations and ratios seen within the 
microporated spheres for proper comparison. Specifically, 2 mL of TRIS buffer and 100 
µL of 1 mg/mL ConA were added to the cuvette. 50 µL of glycosylated dendrimer was 
then added and given 1 hour to equilibrate and fluorescent measurements were taken 
 34 
 
resulting in an assay with 450 nM ConA & 2.3 µM dendrimer. Aliquots of glucose were 
added to the system making glucose concentrations in step-wise fashion up to 1000 
mg/dL. Steady state measurements were taken upon each addition after giving time for 
the system to equilibrate. Three runs were performed for the titration in free solution and 
triplicate data was recorded for each run. 
For the leaching experiments, 500 µL of both groups of microspheres that had 
not been exposed to glucose were packed in microcuvettes with the addition of 2 mL of 
TRIS buffer and given time to settle. Triplicate fluorescence spectra were then taken for 
baseline, 0 mg/dL glucose, measurements. Equivalent dilution factors were performed 
on each cuvette by adding 60 µL aliquots of 200 mg/mL glucose solutions to the settled 
spheres without perturbation to achieve glucose saturated solutions (600 mg/dL). To 
allow for the maximum response and any subsequent leaching, the spheres were given 
twenty-four hours upon the addition of glucose prior to triplicate fluorescence spectra 
being taken. Supernatant was then collected from the microcuvette and triplicate 
fluorescent spectra were taken to quantify the amount of leaching, if any, of the 
fluorescently labeled ConA from within the microspheres. 
The reversibility of the system was tested by packing 500 µL of microporated-
PEG into a microcuvette and adding 2 mL of TRIS buffer. These spheres were allowed 
to settle, and triplicate baseline fluorescent readings were taken for each. A highly 
concentrated aliquot of glucose was then added to make the resulting solution 300 
mg/dL. Fluorescent readings were taken again six hours after the glucose was added to 
the cuvette to be assured the system was at steady-state. The remaining buffer in the 
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microcuvette was then exchanged 4 times that evening, and exchanged 3 times the 
following morning to assure that the glucose concentration was effectively zero. This 
entire process was repeated for fourteen consecutive days. 
Per the technique previously described, the average diameter of the microporated 
spheres was determined to be 545 µm with a standard deviation of 242 µm. In 
comparison, the average diameter of the PEG-50 spheres was determined to be 476 µm 
with a standard deviation of 174 µm. As the ultimate application for these spheres is to 
be minimally invasive subcutaneous interstitial glucose sensors, they must be capable of 
being embedded interstitially. Therefore, future work will focus on reducing the average 
diameter by decreasing the size of the emulsified PEG droplets. However, for 
comparison purposes in this study the two sets of spheres were roughly the same size on 
average. 
The crux of this work depends on the ability for pockets to be created that allow 
the ConA/glycosylated dendrimer sensing assay to be held within a tight polymeric mesh 
but also allow for diffusion of the glucose analyte and room for the aggregative assay to 
respond to the glucose concentration. From the fluorescence confocal microscopy 
images, the differences between PEG-50 spheres and microporated spheres are 
visualized. With a step size in the Z direction of 2.38 µm, these images show a slice 
through the interior of the spheres which display the fluorescent ConA particles. For the 
microporated microspheres, the fluorescence is localized within striated pockets which 
are the residual imprint of sugar crystals that had since been dissolved. The average 
volume fraction of these pores is approximately 1% when accounting for the v/v% ratio 
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between mannitol within the PEG precursor. In comparison, there is no such localization 
for PEG-50 spheres Figure 10. PEG-50 spheres do show a relatively homogenous 
distribution of fluorescence; however, this distribution is a result of the non-localized 
withholding of sensing chemistry. Ultimately, it may be beneficial for the microporated 
microspheres to have a more homogenous distribution of size and distribution of pockets 
since a disperse population of sensing spheres with regard to these variables could result 
in a response that is dependent on which spheres are being interrogated. Future work will 
be done to minimize the variability by increasing the porogen to PEG ratio, increasing 
the speed of the homogenizer, adding surfactant to the precursor, and using a 
centrifugation/filtration system to retrieve the desired sphere-size. 
 
 
Figure 10: Hybrid fluorescence and bright-field images of the (A) PEG50 microspheres 
and (B) microporated microspheres.  (Reference bar is 100 µm) 
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Typically, the sensing response for an assay is inhibited by the specific 
attachment strategy due to the manipulation of the free binding kinetics. For an 
aggregative assay like the ConA/glycosylated dendrimer system described here, such 
strategies would result in prohibiting any response by preventing the mechanism, 
aggregation, to take place. Since this strategy does not purposely employ the use of a 
covalent/ionic attachment, and instead allows the chemistry to remain free within pores 
it was hoped that the sensing response would be present and similar to that seen in 
solution. Figure 11 displays the titration response to monotonic increasing 
concentrations of glucose for microporated microspheres.  
 
 
Figure 11: Fluorescence response of the assay containing microporated microspheres to 
glucose concentrations. 
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The microporated response is relatively linear from 50 to 200 mg/dL with a 
sensitivity of 1.3% per 10 mg/dL, and the response at 200 mg/dL is at 75% of the total 
response of the sensor. For comparison, Figure 12 displays the fluorescent response for 
the sensing assay in solution across physiological concentrations of glucose as compared 
to the microporated response – displaying a linear response through 500 mg/dL of 
glucose and a sensitivity of 1.8% per 10 mg/dL. Above 500 mg/dL, the sensitivity 
decreases to approximately 0.4% per 10 mg/dL. In free solution, the sensing chemistry is 
at approximately 35% of the linear dynamic response at 200 mg/dL. The microporated 
sensing spheres do show a slightly greater sensitivity through the hypoglycemic range 
(0-100 mg/dL); however, there is an overall decrease in the dynamic range and 
fluorescent signal. A possible explanation for this decrease includes the variable loading 
of sensing components since the ratio of free/bound competing ligand is dependent on 
the concentration of the receptor and competing ligand for steady-state glucose 
concentrations. Therefore, any change in either the ConA or glycosylated dendrimer 
concentration within the pores will shift the response in a manner similar to that 
observed. This shift can also be attributed to the confinement of the aggregative sensing 
assay within pores, a process that can theoretically shift the distribution of aggregates to 
favor smaller particles in comparison to free solution with a given glucose concentration 
because of entropy requirements and steric hindrances presented by the pores. As the 
fluorescent response is dependent on the extent of competitive binding, this shift in 
aggregation can shift the response to mimic that seen at higher glucose concentrations of 
the assay in free solution. 
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Figure 12: Comparison of the normalized fluorescence response of the assay in solution 
and microporated microspheres. 
 
 
The standard deviation seen in the titration response of the microporated spheres 
was also higher than that for the free assay. This can be attributed to the variation which 
was seen in the poration of the spheres. The rinsing of spheres required to eliminate the 
glucose within the buffer between runs may have resulted in a different subset of spheres 
being interrogated each time that ultimately could add noise to the system. As previously 
mentioned, the dynamic range of the assay is a function of the aggregation associated 
with competitive binding between the ConA and glycosylated dendrimer. Therefore, the 
fluorescent response it is primarily dependent on the equilibrated glucose concentration. 
However, since the sensing chemistry is aggregative is nature, the dynamic range would 
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be dependent on the size of the pores that contain the assay if they limited the extent of 
aggregation. The dynamic range of the sphere size should be independent of the 
individual sphere size and porosity, given that they allow for the appropriate size for 
individual pores. 
The response time of the sensing chemistry within the spheres is primarily 
dependent on the diffusivity of hydrogel, the size of the spheres, and the porosity 
(volume fraction) of the spheres for whatever system they are placed in. Specifically, 
higher diffusivities should decrease response time for equilibrium, larger spheres should 
increase diffusion distances and increase response time, and higher porosity should 
decrease diffusion distances and decrease response time. 
The quantification of the leaching from within the microporated microspheres 
and PEG-50 microspheres is displayed by Figure 13. Upon 24 hours of exposure to 
highly concentrated volumes of glucose (600 mg/dL), the supernatant showed 
insignificant values of fluorescence from the fluorescently labeled ConA for 
microporated microspheres indicating that no leaching had occurred. In comparison, the 
plot of the fluorescence from the supernatant for the PEG-50 microspheres shows 
approximately 20% of the original fluorescence signal from the fluorescently labeled 
ConA and confirms the problematic leaching associated with the PEG-50 polymeric 
mesh for encapsulation purposes. For these PEG-50 microspheres, the aggregates are 
sufficiently large to remain entrapped within the polymeric crosslinks at low 
concentrations of glucose. However, upon the addition of glucose, ConA competitively 
binds to the analyte rather than the glycosylated dendrimer – decreasing the size of the 
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aggregates. The fluorescently labeled ConA chemistry attached to the glucose as well as 
the free glycosylated dendrimer is then capable of diffusing outwardly, into the 
supernatant. In contrast, the 100% PEG around the pores of the microporated 
microspheres seen via confocal microscopy is capable of withholding the assay 
throughout physiological concentrations of glucose due to the tighter mesh. As 
previously described, the long-term application of any sensing scheme requires an 
effective encapsulation/attachment method which disallows the undesirable release of 
key chemistry components. This leaching is effectively eliminated via the microporation 
technique and provides long-term functionality for the aggregative assay. 
 
 
Figure 13: Fluorescence leaching studies from the microporated and PEG50 sensing 
spheres. 
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Fluorescent opto-chemical sensors often lose their functionality as a result of 
irreversible binding of the sensing components, photobleaching of the fluorophore, 
leaching of the chemistry, and/or the denaturing of the tertiary structure for the binding 
receptor.
37,108
 In an attempt to address part of this potential problem with reversibility, 
glycosylated dendrimer was used in this system to avoid the increased binding affinity 
from a tetrameric unit of ConA binding to multiple sites, such as what may occur for a 
long chain like dextran, and by using AF 647 which is more resistant than other 
fluorophores, such as the rhodamine dyes, to photobleaching. As displayed in Figure 14, 
the microporated microsphere sensor is shown to respond to cycling from 0 to 300 
mg/dL glucose concentration over fourteen days. The key result is that there is 
reversibility with no drop off toward the end of the two weeks, a result that has not been 
previously displayed. In terms of absolute count, the signal from the microporated 
spheres shows a declining trend. The majority of the aforementioned reasons for such a 
loss in functionality should be exponential in nature, but this absolute response does not 
appear to have a true exponential decay. This could be due to the combination of the 
effects on the aggregative assay. However, the relative increase from 0 mg/dL to 300 
mg/dL each day shows no such trend. Therefore, a ratiometric sensing scheme using two 
fluorophores could be employed to maintain long-term functionality and reversibility. 
The relative results do show fluctuations in the response from day to day; however, as 
previously mentioned, we believe the variability in the relative readings between days is 
a result of polydispersity of the spheres in both the size and poration. Nonetheless, the 
data convincingly shows that microporated microspheres can effectively allow the 
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sensing assay to remain functional and reversible to varying glucose concentrations 
through fourteen days at ambient conditions. 
 
 
Figure 14: Reversibility studies for the glucose response of the microporated 
microspheres. 
 
 
In this work, the ConA/glycosylated dendrimer glucose sensitive assay is shown, 
for the first time, to remain functional to varying glucose concentrations within 
polymeric microspheres. A microporation technique is used in which assay-filled pores 
are created within a polymeric mesh that allows the diffusion of glucose to the interior 
pockets while withholding the chemistry from outwardly diffusing throughout the 
competitive binding response. In addition, the microporation synthesis was shown to be 
advantageous for the aggregative sensing chemistry for several reasons: (1) it does not 
require the addition of powerful solvents to dissolve the porogen that could disrupt the 
tertiary structure of the protein, (2) the PEG hydrogel is hydrophilic and biocompatible 
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which allows it to ultimately be implanted within the dermal layers of the tissue, and (3) 
the cross-linking between PEG chains is covalent which is not susceptible to 
electrostatic binding of the sensing chemistry to the inner surface. As a result, the 
sensing spheres were shown to be responsive to glucose with a sensitivity of 1.3% per 10 
mg/dL glucose from 50 to 200 mg/dL. In addition, because of the tight mesh 
surrounding the pores, there was shown to be effectively no leaching of the fluorescently 
labeled ConA from within the microporated microspheres. 
 
Determining the Mechanism of the Sensing Assay 
As the exact mechanism behind the sensor based on ConA and the glycosylated 
dendrimer is not well understood, a more thorough exploration into the dynamics was 
performed.  Because ConA is a multivalent receptor and glycosylated dendrimers 
present multiple ligands, it is possible that the competitive binding that occurs is no 
longer simply a monovalent interaction.  After ConA binds to a single glycosylated 
dendrimer, it can continue to bind to additional glucose moieties if given the appropriate 
binding conditions.  Many groups have shown the extensive crosslinking that occurs 
between receptors that have multiple binding sites and ligands that have multiple 
moieties capable of being bound.
51,109,110
  Therefore, this ConA/glycosylated dendrimer 
competitive binding chemistry could continue to crosslink over time.  This extensive 
crosslinking could result in multiple pathways that decrease the fluorescence intensity of 
the AF647-ConA.  This work attempts to measure how much (if any) aggregation is 
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actually displayed in a solution of ConA and glycosylated dendrimer by using 
Nanoparticle Tracking Analysis (NTA).   
This NTA technique uses Stokes-Einstein equation to compare the motion of 
particles to the Brownian motion of spherical particles.  Therefore, a histogram of 
particle sizes can be created from following the particle‟s motion.  This was performed 
with Nanosight‟s LM10 instrument.  Briefly, a 65 mW, 488 nm laser line was projected 
horizontally across a sample solution of 500 microliters.  The particles that scatter this 
light within this plane are imaged using a 20X objective to focus the scattered light onto 
the EMCCD.  Frames are taken over time and image processing is performed to follow 
the movement of individual particles.  By following individual particles, this technique 
has been shown to be more effective than Dynamic Light Scattering (DLS) in 
determining the size distribution of a sample containing particles of mixed sizes.
111
   
For this experimental set up, two sensing assays were created with 250 nM AF-
647 Concanavalin A and 2 µM G2-NH2 glycosylated dendrimer in TRIS buffer.  TRIS 
buffer was composed of 0.15 M NaCl, 0.01 M TRIS base, 1 mM CaCl2, and 1 mM 
MnCl2 at pH 7.4.  One assay had no glucose added (A), and the other had glucose added 
at a final concentration of 100 mg/dL. The solution was given ten minutes to equilibrate.   
The solution was then added into the sample chamber of Nanosight‟s instrument and 
measurements were performed.   
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Figure 15: Glucose-dependent aggregate distribution for the ConA/glycosylated 
dendrimer assay. 
 
 
Figure 15 shows the size distribution profile for these assays.  The original sizes 
of the ConA and glycosylated dendrimer are 8 nm and 1.5 nm, suggesting that 
monovalent complexes between the ConA and dendrimer would be 10 nm.  However, 
these results show that an assay that pairs ConA with this glycosylated dendrimer can 
form aggregates that are larger than 300 nm in diameter, indicating that a significant 
amount of aggregation is occurring.  The distribution profiles of the two glucose 
concentrations suggest the addition of glucose shifts the aggregates to smaller sizes.  It is 
expected that this trend would continue for increasing concentrations of glucose.   
The aggregate distribution was expected to be broad, but it was expected to have 
a single maximum value with monotonic decays to both sides.  The distribution for the 
100 mg/dL glucose concentration resembles that expectation, but the distribution for 0 
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mg/dL does not have that characteristic shape.  The leftmost peak for the 0 mg/dL 
distribution curve could be an example of an unreactive or damaged portion of the 
Concanavalin A where that mode is generated from aggregates reaching an ideal size.  
Other possible explanations could be related to the time response of the sensing 
chemistry – either we did not wait long enough for full aggregation to occur or the assay 
was actually falling out of solution.     
 
Table 3: Results from NTA of ConA-based assay with glycosylated dendrimer. 
Assay Response 0 mg/dL glucose 100 mg/dL glucose 
Average Diameter (nm) 194 156 
# Particles (*10
8
/mL) 3.06 8.32 
 
 
Table 3 shows the average particle diameter and number of particles in each 
solution.  From these preliminary results, it appears that glucose decreases the mean size 
of aggregation and increases the number of particles within the system.  This agrees with 
the concept that the aggregation is glucose dependent.  The binding events to glucose 
would decrease the total number of receptors available for crosslinking to the 
glycosylated dendrimer.  As the particle size decreases, the number of aggregates found 
in the system increases because the total dendrimer and receptor concentration remains 
constant.  
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Additional studies were attempted to explore this idea further, but showed 
limited success.  Tracking the profile of aggregate size proves difficult because as 
aggregates grow larger, they have the propensity to fall out of solution.  Figure 16 shows 
an example of an assay that had been prepared for NTA analysis, but had been left in 
solution for 2 hrs.  This falling out of solution could explain the extreme changes in 
fluorescence that had been seen from labeled ConA, even when it was intended to be the 
FRET-acceptor.  When the assay was loaded into similar cuvettes and tested using a 
traditional spectrofluorometer, the fluorescent material could have just fallen out of 
solution.   
 
 
Figure 16: Visual precipitation of ConA-based assay paired with G2-NH2 dendrimer in 
the absence of glucose. 
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This type of aggregation cannot be tracked with NTA, because the technique 
requires the particles to be suspended in solution.  Stirring the solution could potentially 
keep the aggregates in solution, but it would induce a particle motion that would be 
difficult to subtract for in the NTA program, and the kinetics of the assay would be 
different.  As a result, the aggregation-studies using NTA were postponed and the design 
of the glycosylated dendrimer was examined further. 
The glycosylated dendrimers that have traditionally been paired with ConA by 
our group have presented glucose moieties and amine functional groups at the surface of 
the molecule.  Originally, this was a consequence of using the amine-reactive chemistry 
to attach glucose molecules (using either glucosyloxyethyl methacrylate or 
isothiocyanatophenyl β-D-glucopyranoside).67,88,89  In those glycosylated dendrimers, a 
percentage of the primary amines were left unconjugated and left on the dendrimer.  
Each of the dendrimers tested from Dr. Simanek had also presented primary amines at 
the surface of the glycosylated dendrimer with the addition of 4-aminomethyl piperidine 
(4-AMP) as the last step of the triazine chemistry.
66,112,113
  To explore the role that these 
primary amines have on the response of the glycosylated dendrimer, an alternative 
version of the glycosylated dendrimer was generated by Dr. Simanek that presented 
hydroxyl groups in their place (using 4-piperidinemethanol (4-PPM) instead of 4-AMP).  
Generation two dendrimers with 12 glucose groups and 12 hydroxyls (G2-OH) were 
compared to the generation two dendrimers with 12 glucose groups and 12 primary 
amines (G2-NH2).   
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In separate microplate wells, three solutions were made that each had a final 
volume of 300 µL.  Each solution was in TRIS buffer (pH 7.4) and had 500 nM AF647-
ConA. One of the solutions had no dendrimer.  One had 500 nM G2-OH dendrimer, and 
the other had 500 nM G2-NH2 dendrimer.  The peak fluorescence intensity of the 
AF647-ConA was measured, and these fluorescence intensities are shown in Figure 17.   
 
 
Figure 17: Fluorescence intensity of 500 nM AF647-ConA in the absence and presence 
of two different dendrimers (G2-NH2 and G2-OH). 
 
 
This shows that the G2-OH dendrimer does not decrease the fluorescence in the 
same way that the G2-NH2 dendrimer does.  This could be due to the G2-OH dendrimer 
not binding to ConA at the same affinity, possibly due to a decreased amount of non-
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specific electrostatic interactions.  A primary amine typically has a pKa around pH 9 and 
ConA‟s isoelectric point is ~5.  Therefore at pH 7.4 in TRIS buffer, the dendrimers 
should display a net positive charge with multiple positive charges while ConA should 
display a net negative charge with multiple negative charges.  The multiple charges on 
each molecule can allow for non-specific interactions to cause the cross-linking.  In 
addition, this could be why the AF647-ConA that is labeled in our lab has generally 
displayed a more dynamic response than that which is purchased.  The higher degree of 
labeling could make the ConA more negatively charged which would presumably 
increase the electrostatic interactions.  It is also important to identify the conformation of 
the glucose moieties that are presented on the surface as ConA is shown to bind to the 
alpha-conformation of glucose much stronger than the beta-conformation.
52
  
The decrease in quenching efficiency for the G2-OH dendrimer could also be 
that the quenching of the fluorescence actually has something to do with the amines.  
Deprotonated amines have been shown to undergo photo-induced electron transfer 
(PET) with various fluorophores.
114
  AF647 is a cyanine based dye, and it is very likely 
that there are several deprotonated primary amines on the surface of the dendrimer at 
physiological pH due to the high level of crowding on a single dendrimer.
115
  Upon 
aggregation, it is likely that fluorophores would be in close proximity to deprotonated 
primary amines.  This could allow PET to occur.   
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Visual Precipitation  
To have a qualitative understanding of the binding affinity, precipitation 
experiments were performed by pairing ConA with various ligands.  Separate centrifuge 
tubes were loaded with 500 µL of 500 nM AF647-ConA and 500 nM of one of the 
following: (a) 500 nM G2-NH2 dendrimer, (b) .005 w/v% poly-l-lysine (PLL), or (c) 
500 nM G2-OH dendrimer. The PLL is a polypeptide that has no glucose residues but 
displays many primary amines and is expected to be positively charged at physiological.  
A centrifuge tube of 500 nM AF 647-ConA was used as a control.  Each of these 
solutions was in TRIS buffer.  These solutions were allowed to interact with each other 
for 30 minutes, and then were centrifuged to force aggregates to fall out of solution.  
These centrifuge tubes were then examined for visual precipitation.   
These experiments showed that the solutions with G2-NH2 dendrimer and PLL 
show visual precipitation (blue dot at the bottom from the AF647).  The AF647-ConA 
control and the solution with G2-OH dendrimer do not show precipitation.  This 
suggests that a good portion of the binding is due to the electrostatic interactions 
between ConA and the G2-NH2 dendrimer.   
 
Glucose Response with PLL 
To examine this more closely, an assay based on AF647-ConA and PLL was 
generated and exposed to glucose.  Three microplate wells were loaded (final volume 
300 µL) with a final concentration of 500 nM AF647-ConA in TRIS buffer.  Two of 
these wells were loaded with a final concentration of 0.005 w/v% PLL.  Finally, one of 
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those was loaded with a final concentration of 1000 mg/dL glucose.  The wells were 
excited with 620 nm light and emission was collected from 650 nm to 720 nm to look at 
the emission from the AF647-ConA.  This response is shown in Figure 18. 
  
 
Figure 18: Fluorescence of 500 nM AF647-ConA in TRIS buffer (pH 7.4) (black), 
paired with PLL without glucose (red) and paired with PLL with glucose (blue). 
 
 
Figure 18 shows that the fluorescence significantly decreases with the addition of 
the positively-charged PLL, in a very similar manner to the G2-NH2 glycosylated 
dendrimers.  This could be attributed to aggregation induced by electrostatic interactions.  
The decrease in fluorescence could be due to scatter from the aggregation, falling out of 
solution due to the aggregation, PET from the aggregation, and energy transfer from the 
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aggregation.  Upon addition of glucose, there is an 18% increase in the fluorescence 
intensity.  While this isn‟t as large as the increases that have been seen with the G2-NH2 
glycosylated dendrimer, it seems higher than error of the microplate reader and/or 
loading of the microplate.  This indicates that the addition of glucose changes the 
electrostatic interactions between ConA and the PLL in some way.  It could be due to 
glucose‟s ability to form Schiff bases with the amines on the PLL. This could potentially 
decrease the net charge of the PLL and could increase steric hindrances due to the open-
chain glucose molecules extending from the PLL.  These changes would decrease the 
electrostatic interactions and potentially break up the aggregation between the PLL and 
the AF647-ConA to allow fluorescence to be regained.   
The same experiment was performed in bicarbonate buffer at pH 10.25 in an 
attempt to decrease the overall net charge on the PLL.  This pH is above the pKa of 
lysine‟s primary amines and should cause the majority to be deprotonated.  The results 
are shown in Figure 19.  The addition of PLL displays less of a decrease to the 
fluorescence in comparison to the decrease seen in TRIS buffer.  This suggests that the 
electrostatics play a significant role in the binding between G2-NH2 glycosylated 
dendrimers and ConA.  The addition of the glucose again shows an increase in the 
fluorescence.   
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Figure 19: Fluorescence of 500 nM AF647-ConA in bicarbonate buffer (pH 10.25) 
(black), paired with PLL without glucose (red) and paired with PLL with glucose (blue). 
 
 
This combination of results indicates that a net positive molecule without glucose 
residues can cause a decrease in the fluorescence of the AF647-ConA.  In addition, it 
shows preliminary results that the fluorescence from such an assay can be increased 
upon the addition of glucose.  This ConA/PLL assay does not have any specificity, 
because the PLL does not display moieties that can attach to the glucose binding site on 
ConA.   
This exploration into the mechanism of the ConA/glycosylated dendrimer assay 
indicates that it is very complex sensing assay.  It shows that the glycosylated dendrimer 
approach has used a combination of specific binding and electrostatic interactions to 
cause the binding to ConA. In addition, it has multiple possible pathways that can cause 
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decreases in measured fluorescence intensity.  Since both assay components display 
multiple specific and nonspecific sources of interaction, it is not surprising that the assay 
shows a significant amount of aggregation in free solution.  These aggregates were 
measured to reach several hundred nanometers in size, and were even visible to the eye 
after a fairly short amount of time.  This aggregation can cause fluorescence responses in 
a myriad of different ways.  It could significantly decrease the fluorescence intensity of 
an assay in a cuvette by just falling out of the beam-path - which is not expected to 
translate into a percutaneous or fully implanted sensor.  The portion of the amines on the 
glycosylated dendrimer that are deprotonated could also undergo photo-induced electron 
with the fluorophore.  To allow an assay to remains stable in free solution, it is essential 
to use a fluorescent ligand that simplifies the binding and fluorescence mechanisms. 
 
Conclusions 
For a sensor to be useful, it must be capable of responding in a predictable 
manner.  To date, the ConA-based glucose sensor that uses the glycosylated dendrimer 
has shown problems with repeatability, and preliminary experiments suggest that a large 
portion of the quenching is due to aggregation that can cause the complexes to 
completely fall out of solution.  This aggregation requires a unique strategy for 
encapsulation purposes.  At its very best, this type of assay is a complex system that (1) 
does not follow typical competitive binding theory, (2) relies on non-specific 
electrostatic interactions, (3) and employs an aggregation mechanism that can allow the 
entire assay to fall out of solution.  Receptors are used in binding assays to give it 
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specificity.  The electrostatic interactions are seen with the primary amines on the 
glycosylated dendrimers are non-specific and decrease the specificity of the assay.  The 
fluorescent competing ligand paired with ConA could eventually use a glycosylated 
dendrimer approach, but the dendrimers would need to be redesigned to cause a specific, 
predictable binding response to ConA. 
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CHAPTER III 
MATHEMATICAL MODEL OF CONA-BASED GLUCOSE SENSOR BASED ON 
COMPETITIVE BINDING WITH FLUORESCENCE ANISOTROPY
*
  
 
Introduction 
Because the glycosylated dendrimer approach displayed problems with 
repeatability, reversibility, and specificity, a mathematical model was generated to guide 
the design of an optimized assay.  Instead of allowing the recognition and transduction 
mechanisms to be dependent on each other, the goal is to design this assay to have them 
independent.  Accordingly, these mechanisms are modeled independently to identify 
specific characteristics for the assay that maximize the fluorescence response to 
physiological glucose concentrations.   
Fluorescent ConA-based sensors have typically used FRET to transduce the 
equilibrium binding with changes to either the fluorescence intensity or fluorescence 
lifetime.  For a ConA-based assay with given association constants for the CL and 
glucose, there exists an ideal set of concentrations of ConA and CL at which the greatest 
change in binding will occur across the physiologically-relevant glucose range.  
However, the typical transduction mechanism of FRET requires the concentrations of 
                                                 
*
 Part of this chapter is reprinted from B. M. Cummins, and G. L. Coté, "A fluorescence polarization based 
assay for glucose sensing." 8229 (2012), with kind permission of SPIE, Copyright 2014; from B. M. 
Cummins, J. T. Garza, and G. L. Coté, “Optimization of a concanavalin A-based glucose sensor using 
fluorescence anisotropy,” Analytical Chemistry, 85(11), 5397-5404 (2013), with kind permission of ACS, 
Copyright 2014.; and from B. M. Cummins, J. T. Garza, and G. L. Coté, "Limitations of current 
fluorescent glucose sensing assays based on competitive binding." 8591 (2013), with kind permission of 
SPIE, Copyright 2014. 
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the fluorescently labeled ConA and the fluorescently labeled CL to be on the same order 
to avoid significant amounts of non-specific absorption/quenching and spectral bleed-
through by the FRET acceptor.  This coupling of the transduction and recognition 
mechanism makes FRET a non-ideal technique to study the binding profile at the full 
range of assay concentrations.  Therefore, unless the association constant between ConA 
and the CL is already tuned, the experimentally observed FRET response will not 
display the full-potential of the assay at the configuration that maximizes binding.  
Ideally, the binding would first be optimized for concentrations that can work for FRET, 
and the assay components would then be labeled with appropriate fluorophores to allow 
FRET to occur.  A brief schematic of a FRET-based assay is shown in Figure 20.   
 
 
Figure 20:  Schematic representation of a FRET assay based on competitive binding 
with ConA. 
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  ConA-based assays have typically been generated by developing a unique CL 
and recording the FRET response of various ConA and CL concentrations against 
physiological concentrations of glucose.  The concentration pair that elicits the greatest 
change in the measurable signal is identified as the optimized sensing assay.  Because 
this measured signal is effectively the convolution of the recognition and transduction 
mechanisms, the sensor‟s response can misrepresent the full potential ConA has towards 
continuous glucose monitoring applications if both mechanisms are not optimized for the 
final assay configuration.   
Unlike FRET-based approaches that track intensity or lifetime, fluorescence 
anisotropy (FA) is a polarization-based approach.  While it would likely be unsuitable to 
be used in an implantable ConA glucose-sensor because of the highly depolarizing 
scatter from the tissue, it can be used as a transduction mechanism to characterize the 
capability of a ConA-based glucose sensor as long as the environment is low in 
scattering and the size of the CL is relatively small.  Specifically, because FA requires 
only one labeled population, it can allow for both mechanisms to be fully optimized for a 
given assay configuration.  Thus, the technique offers the user the capability of exploring 
a wider range of concentrations for a given set of association constants without the 
aforementioned transduction/recognition coupling concerns.  By decoupling and 
independently optimizing these two mechanisms, it is possible for the sensitivity of the 
assay towards glucose to be enhanced and the true capability of ConA to be realized.   
This chapter introduces a mathematical model for the recognition mechanism 
(competitive binding) and the transduction mechanism (fluorescence anisotropy) to 
 61 
 
identify characteristics of an optimized fluorescence anisotropy competitive binding 
assay to track physiologically relevant glucose concentrations.  Various assay-
configurations based on the 4-kDa FITC-dextran fluorescent ligand are shown to 
validate the model.  The results of this model are then presented in 2D sensitivity maps 
to clearly display the regions that are ideal for such an assay, and specific qualities are 
identified to optimize the anisotropy assay and other assays based on FRET.  This 
description is then used in an attempt to describe the historical problems with ConA-
based glucose sensors.   
 
Mathematical Model 
The ultimate goal for a fluorescence competitive binding assay is to be able to 
track the concentration of an analyte of interest with the fluorescence from that sample.  
The competing ligand is chosen to be the fluorescent ligand that is tracked in this assay 
because it gives us more control and avoids potential problems with protein 
denaturation.  Here, we introduce a model for a fluorescence anisotropy competitive 
binding assay based on ConA for glucose sensing that tracks the fluorescence from the 
competing ligand. 
 
Background and Theory 
Fluorescence anisotropy (FA) has been extensively used within the field of 
biochemistry to explore molecular interactions.
116
  More specifically to this work, FA 
has been used as a transduction technique in the field of glycobiology to determine 
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association and inhibition constants for various sugars.
117-119
  These assays have recently 
been complemented with high throughput glycan arrays to allow for the quick 
determination of interactions between a receptor and a diverse set of glycans.
120-122
  FA 
remains a powerful spectroscopic technique to transduce events occurring on the 
molecular level.   
Briefly, FA is a homogeneous and reproducible method that can be used to 
explore the average rotational diffusion rate of the fluorescently labeled molecules in a 
given system.  By interrogating the system with plane polarized excitation light, 
information can be retrieved about the rotational speed of the fluorescent molecules from 
the polarization of the fluorescence.  In an FA measurement, vertically polarized 
excitation light selectively excites the fluorophores in the solution that have the 
appropriately oriented excitation dipoles.  During the period of time that the fluorophore 
is in the excited state, the molecule is free to rotate in solution.  Because larger 
molecules tumble more slowly than smaller molecules, they could display a higher FA 
even if they are labeled with the same fluorophore.  In a binding assay, the portion of the 
fluorescently labeled ligands that are bound can display a higher FA than the portion that 
is free.  This typically requires the receptor to be larger than the fluorescent ligand and 
the appropriate fluorophore to be used.  The schematic in Figure 21 shows an optimized 
assay in which the bound population (bottom) displays a higher FA than the free 
population (top). 
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Figure 21: Schematic representation of the change in rotational speed of fluorescent 
ligands upon binding. (White square: fluorescent ligand, arrow: dipole of fluorophore, 
yellow circle: excited fluorophore, dark circle: receptor) 
 
 
Theoretically, FA (r) can exist from -0.5 to 1, but these limits are only reached 
when all dipoles are aligned upon photo-selection.  In free solution, the dipoles are 
randomly oriented when photo-selection occurs, and the limits of FA are -0.2 to 0.4. In 
practice, the polarized fluorescence intensity is measured in the parallel (    and 
perpendicular (    directions (defined by the polarization of the excitation light), and the 
FA of a sample is calculated as shown in Equation 1.   
 
   
     
      
 (1) 
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In a FA competitive binding assay, the FA will effectively track the average 
rotational speed of the fluorescent ligands in the sample.  As seen in Equation 2, the 
experimentally observed FA (<r>) corresponds to the linear summation of fluorescent 
populations with unique FA values (ri) with regard to their fractional contributions of the 
total intensity measured (fi).  Because our competitive binding assay will be engineered 
to only display two fluorescent populations within the sample – a bound population and 
a free population – this can be written as Equation 3.   
 
     ∑  
 
   
   (2) 
 
               (3) 
 
The glucose-dependent competitive binding changes the fractional fluorescence 
intensity that comes from the bound and free populations.  If we assume that the 
quantum yield of the fluorescent ligand does not change upon being bound, the 
fractional fluorescence intensity that comes from the bound can be described with the 
percent of the fluorescent competing ligand that is bound (%CLB) and Equation 3 can be 
written as Equation 4.  The sensitivity of this assay (the change in the anisotropy across a 
certain glucose range) can then defined by Equation 5.   
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               (         )   (4) 
 
 
    
  
        
     
  
 (5) 
 
This explicitly defines the sensitivity of the assay as a function of the two 
mechanisms involved: the transduction mechanism and the recognition mechanism.  In 
order to maximize the assay‟s sensitivity and generate the ideal sensor, both mechanisms 
need to be optimized.  To optimize the transduction mechanism of the assay, the goal is 
to maximize the change in steady-state anisotropy between the bound and free 
populations        .  The recognition mechanism can be optimized by maximizing the 
change in the %CLB across the glucose range of interest (
     
  
).   
 
Transduction Mechanism: Fluorescence Anisotropy  
To identify characteristics of a competitivve binding assay that can maximize the 
sensitivity associated with the transduction mechanism, the fluorescence anisotropy was 
modeled.  Figure 22 shows a schematic where the fluorescence anisotropy is higher in 
the bound state than the free state.  By using a labeled CL with a low molecular weight 
and a receptor with a high molecular weight, the degree of binding can effectively be 
tracked via FA.    
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Figure 22: Schematic representation of the transduction mechanism for a fluorescence 
anisotropy assay based on competitive binding with ConA. 
 
 
  The fluorescence anisotropy of a given population is the relationship between 
the average time that the fluorophore is in the excited state (fluorescence lifetime) and 
the average time that takes the molecule to tumble (rotational correlation lifetime).  This 
relationship has been described using Perrin‟s equation (Equation 6).  The value ro is the 
intrinsic anisotropy value for a given fluorophore, τ is the fluorescence lifetime of the 
fluorophore, and φ is the rotational correlation lifetime of the fluorophore.  For a 
spherical particle, the rotational correlation lifetime is defined in Equation 7 (M:  
molecular weight, T: temperature in Kelvin, R: universal gas constant, η: viscosity, ν: 
partial specific volume, h: degree of hydration).     
 
     (  
 
 
)⁄  (6) 
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 (7) 
 
This allows the FA to be predicted for various fluorescent ligands according to 
their molecular weight and fluorescence lifetime by modeling Perrin‟s equation (Eq. 6) 
for spherical particles (ro = 0.4, T = 293 K, η = 0.01 cP, ν = 0.73 cm
3
/g, h = 1.17 ml/mg, 
and R = 8.321*10
7
 erg/K∙mol).  To generate an expected FA for the fluorescent ligands 
when they are bound to ConA, the same spherical particle assumption was made and the 
MW used in Perrin‟s equation was increased by 104 kDa (the size of ConA).  These 
predictions assume that (1) the local mobility of the fluorophore is negligible, (2) the CL 
is effectively spherical, and (3) the CL/ConA complex is effectively rigid and spherical.  
The change in FA upon binding to ConA was determined for each theoretical fluorescent 
competing ligand (defined by a fluorescent lifetime and a MW), and these results are 
plotted in Figure 23.  The set of fluorescent competing ligands in Table 4 are identified 
on this 2D sensitivity plot. 
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Figure 23: Modeled change in anisotropy upon binding to ConA for various fluorescent 
ligand properties.  Boxes represent the fluorescent ligands in Table 4. 
 
 
Table 4 shows that the FA of 4 kDa AF 647-dextran is relatively constant at the 
high end of the possible FA range, suggesting that its lifetime is too short to allow the 
glucose-response to be observable via FA.  The fluorophore is expected to fluoresce 
prior to significant rotation of the ligand in both the bound and unbound states.   The 
ruthenium-based fluorescent ligand also appears to be unsuitable to track the competitive 
binding; it appears to lose most of the anisotropy information before it fluoresces 
regardless of whether it is bound. 
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Table 4: Modeled bound and unbound FA values at 293 K in water. 
 
   Competitive Ligand (CL) FA unbound FA bound to ConA 
  A 4 kDa AF 647-dextran 0.303 0.395 
  B 4 kDa FITC-dextran 0.175 0.382 
  C 10 kDa FITC-dextran 0.264 0.383 
  D 70 kDa FITC-dextran 0.373 0.389 
  E 4 kDa Dansyl Chloride-dextran 0.054 0.323 
  F 4 kDa Ruthenium-dextran 0.004 0.088 
 
 
Dextrans with increasing molecular weights were also explored, but the 
difference in FA upon binding is shown to decrease with increasing size of the CL.  
Ligands smaller than 4kDa dextran would increase the predicted difference further; 
however, the association constant would decrease to a level that is unsuitable for 
competitive binding. 
The 4 kDa FITC-dextran and the 4 kDa dansyl chloride dextran appear suitable, 
showing an FA difference of 0.207 and 0.269 between bound/unbound states, 
respectively.  However, dansyl chloride is an environmentally sensitive fluorophore that 
could increase its fluorescence intensity when brought close to hydrophobic residues 
upon dextran‟s binding to ConA.  FITC is insensitive to the environment‟s polarity, but 
is known to be pH sensitive due to its carboxyl and phenol groups.  Fluctuations in pH 
can be minimized by using TRIS buffer at pH 7.4.  Thus, 4 kDa FITC-dextran was 
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chosen as the fluorescent competitor to be used in experimental studies as it should 
generate a suitable change in FA and is commercially available.  The competitive 
binding was then modeled for this specific ligand to predict glucose responses of various 
assays. 
 
Recognition Mechanism: Competitive Binding 
For the modeling of the competitive binding, we make the assumptions that (1) 
the interaction between ConA and the fluorescent ligand can be defined with an 
association constant and that (2) the interaction is monovalent.  This means that if ConA 
and the fluorescent ligand were placed in solution, there would only be two populations 
for each component in existence (bound and free).  We make the same assumptions for 
ConA‟s interaction with glucose.  In addition, we make the assumption that the binding 
of glucose and the fluorescent ligand to ConA is directly competitive.  If ConA‟s binding 
site is bound to glucose, it cannot bind the fluorescent ligand and vice versa.  With those 
assumptions, the following equations can be used.  A schematic representation of the 
competitive binding (the recognition mechanism) is shown in Figure 24.   
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Figure 24: Schematic representation of the recognition mechanism of the fluorescent 
anisotropy assay based on competitive binding with ConA 
 
 
 [  ]  [   ]   [  ]   [   ] (8) 
 [  ]  [   ]   [  ] (9) 
 [  ]  [   ]   [  ] (10) 
     [   ] ([  ]  [  ])⁄  (11) 
     [   ] ([  ]  [  ])⁄  (12) 
 
 In these equations, [Ct], [C-G], [Cf], [C-L], [Lt], [Lf], [Gt], and [Gf] are defined as 
the concentrations of total ConA, ConA bound to glucose, free ConA, ConA bound to 
the competing ligand, total competing ligand, free competing ligand, total glucose, and 
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free glucose, respectively.  The association constant KCL is the affinity of ConA to the 
competing ligand and KCG is the affinity of ConA to glucose.  The association constant 
of tetrameric ConA to glucose and methyl alpha-mannose has been shown to be 400 M
-1 
and 8,200 M
-1
, respectively.
48,123
  The association constant of the tetrameric ConA to the 
competing ligand can be varied by the choice of the competing ligand.    
 The exact solution to Equations 5-7, as described by Wang, can be used to 
determine the expected concentrations of each population at equilibrium.  This is a 
function of the total concentrations of the competing ligand, ConA, and glucose as well 
as the association constants of ConA to the glucose and the competing ligand.
124
  
Therefore, a competitive binding assay can be fully defined by the total ConA and total 
competing ligand in the assay as well as ConA‟s association constants to the competing 
ligand and glucose.  Keeping each of those quantities fixed, the equilibrium binding can 
be solved for a specific glucose concentration.  This solution to the equilibrium binding 
describes the concentration of each of the populations that are found in the solution.  
Multiple glucose concentrations can be solved for to determine the glucose response for 
that „assay.‟     
For a competitive binding assay that fluorescently labels the competing ligand, 
the amount of competing ligand in the bound population needs to change as a function of 
the glucose concentration.  Because we defined the fluorescent competing ligand to only 
be capable of being in two states, this population can be tracked by calculating the 
%CLB.  For a molecule that does not change its quantum yield upon binding to ConA, 
the %CLB is equivalent to the fractional fluorescence intensity that comes from the 
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bound population.  Figure 25 shows the effect that physiological glucose concentrations 
have on the %CLB of three different assays.   
 
 
Figure 25: Modeled responses of fluorescent dextran bound (% CLB) vs. glucose for 
different assay configurations: The change in % CLB from 0 mg/dL to 300 mg/dL for 1, 
2, and 3 is 45%, 27%, and 4%, respectively. 
 
 
The goal of a specific assay is to maximize the absolute change in the %CLB 
across the desired concentration range for the analyte of interest (i.e. glucose).  An assay 
that generates a higher change in the %CLB across this range would be identified as a 
more sensitive assay.  In this set of assays, Assay 1 is identified as being the most 
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sensitive because it has the greatest change across the range of interest.  To identify that 
sensitivity with a figure of merit, this work identifies the range of interest for glucose to 
be 0 mg/dL glucose to 300 mg/dL.  For the %CLB vs. glucose curve for a given assay, 
the difference in the %CLB at these two glucose concentrations is proportional to the 
sensitivity of the assay.  Assay configurations that display similar changes in the %CLB 
across this range should display similar changes in the measured anisotropy across that 
range.   
 For a ConA-based assay that has already chosen its competing ligand (effectively 
fixing the KCL), this model can be used to identify the optimal concentrations for the 
competing ligand and ConA that maximize the sensitivity of the assay.  The model 
sweeps through all possible concentrations for ConA and the competing ligand and can 
generate a map of the change in %CLB for all the configurations. Figure 26 is an 
example where the competing ligand is chosen to be 4 kDa dextran.    Assuming typical 
branching seen in dextrans, 4 kDa dextran should have ~3 non-reducing termini per 
dextran molecule and the effective affinity of ConA to the 4 kDa dextran should be 
~5000 M
-1
.
61
  Using association constants for ConA to glucose and 4 kDa dextran to be 
400 M
-1
 and 5000 M
-1
 (respectively), this shows that the maximum recognition 
sensitivity (~45% change in %CLB) of this assay is expected to be seen for an assay 
composed of ~500 µM ConA with a dextran concentration less than 100 µM.  
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Figure 26: Change in % dextran bound to ConA (% CLB) from 0 mg/dL to 300 mg/dL 
glucose for various ConA and dextran (D) combinations.  Top inset: Change in % CLB 
vs. [ConA] with [D] fixed at 1 µM (dotted line). Right inset: Change in % CLB vs. [D] 
with [ConA] fixed at 500 µM (solid line). 
 
 
Dextran concentrations higher than 100 µM (for a fixed concentration of ConA at 
500 µM) begin to show a decreased response to glucose because the % CLB at 0 mg/dL 
glucose begins to decrease. A similar response is observed using an optimized dextran 
concentration (1 µM with concentrations of ConA significantly below 500 µM.  For 
concentrations of ConA that are significantly higher than 500 µM ([dextran] at 1 µM), 
the addition of glucose to physiologically-relevant concentrations has little effect on the 
 76 
 
% CLB.  Even after the binding of glucose, there is sufficient ConA available to bind the 
majority of the fluorescent dextran at these ConA concentrations.   
The full %CLB vs. glucose responses of various assay configurations are shown 
in Figure 27 and Figure 28.  Figure 27 shows the responses of assays with various ConA 
concentrations (5 µM-100 mM) for a fixed dextran concentration (100 nM).  Figure 28 
shows the responses of assays with various dextran concentrations (100 nM-10 mM) for 
a fixed ConA concentration at 500 µM.   
 
 
Figure 27: Modeled %CLB vs. [glucose] for competitive binding assays based on 1 µM 
dextran and varying [ConA]. 
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Figure 28: Modeled % CLB vs. [glucose] for competitive binding assays based on 500 
µM ConA and varying [dextran].  
 
 
In reality, an assay that uses 4-kDa dextran as the competing ligand cannot 
achieve the maximum sensitivity of the assay (as defined by change in %CLB).  The 
solubility limit of native ConA in a physiologically relevant buffer has been shown to be 
~100 µM.  Therefore, ConA concentrations cannot be higher than this in a stable assay 
in free solution.     
While we have shown that this model can identify the ideal concentrations of 
ConA and competing ligand for a given competing ligand, this model can also be used to 
help identify an ideal competing ligand to optimize the assay binding.  By fixing the 
concentration of the fluorescent ligand in the solution, one can predict the glucose 
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responses for a given KCL and [ConA].  In real fluorescence measurements, it is often 
desirable to limit the concentration of the fluorophore in the solution to avoid inner-filter 
effects.
125
  According to the degree of labeling of the fluorescent ligand, this fixes the 
concentration of the fluorescent ligand.  Figure 29 is a log-log plot that shows a 2D 
sensitivity plot for a fluorescent competing ligand concentration of 500 nM.  The 
recognition sensitivity is plotted as a function of the ConA concentration and the KCL.   
 
 
Figure 29: Change in %CLB across physiological glucose concentrations (recognition 
sensitivity) for 500 nM fluorescent ligand (CL) as a function of the [ConA] and KCL. 
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In this figure, the blue regions show very little change in the %CLB across the 
previously identified glucose concentration range.  The red portions of the graph indicate 
the largest possible changes in the %CLB across this range.  The maximum value for 
this change is approximately 45% and is a result of the association constant between 
ConA and glucose.  For the glucose concentration range of interest (0 mg/dL-300 
mg/dL), it is not possible to have a larger change in %CLB with native ConA.   
 This 2D plot shows that by increasing the apparent affinity between ConA and 
the competing ligand, you require a lower concentration of ConA to track the binding to 
glucose.  This provides some insight as to why groups have typically used multivalent 
competing ligands in ConA-based assays.  The affinity to monosaccharides is typically 
low (~10
3
 M
-1
), and would require ConA concentrations that are above the solubility 
limit of ConA.
126
  By increasing the affinity to ConA with multivalent competing 
ligands, the maximum sensitivity can be achieved with the appropriate ConA 
concentration.   
It is important to note that the concentration of the competing ligand that is 
chosen only changes where the sensitivity trails off at the lower-right portion of the 
graph.  This trail-off point happens at a ConA concentration that is roughly 2 times the 
chosen competing ligand concentration.  At ConA concentrations lower than this, there 
is not enough ConA to bind a considerable portion of the competing ligand.  By 
choosing a higher competing ligand concentration, the trailing off region would happen 
along this diagonal at higher concentrations of ConA.  Lower competing ligand 
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concentrations would allow lower ConA concentrations (and higher affinity ligands) to 
be used and still achieve maximum sensitivity for the recognition mechanism. 
 
Validation of Model  
This model was then validated with experiments with the 4 kDa FITC-dextran 
competing ligand.  For the assay configurations listed in Table 5, the expected FA vs. 
glucose responses were modeled for physiologically relevant glucose concentrations (0-
500 mg/dL) with Equation 2.  These responses were calculated by using the FAi and fi 
values that were previously predicted for 4k-FITC-dextran.  The FAi from Equation 2 
was replaced by the FAbound and FAunbound for 4 kDa FITC-dextran populations from 
Table 4.  The fi in Equation 2 was replaced by the appropriate % CLB value as predicted 
by the competitive binding modeling.  Again, this can be done by assuming the quantum 
yield to stay constant upon binding.  Because the % CLB is a function of glucose, the 
observed FA is dependent on glucose concentration in the system. 
 
Table 5: List of assay configurations tested in the validation of model. 
Assay Configuration [4 kDa FITC-Dextran] (nM) [ConA] (µM) 
1 100 100 
2 1000 100 
3 100 10 
4 100 1 
5 100 0.1 
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The assay configurations were chosen to display a range of predicted sensitivities 
to demonstrate the effectiveness of the FA-competitive binding model.  Unfortunately, 
the assay configuration that showed the maximum sensitivity was not able to be 
generated due to the solubility limit of ConA, but some assay configurations were 
chosen to achieve the maximum possible sensitivity for this competing ligand.  All 
assays are assumed to have the same FA values for the bound and unbound dextran 
populations because the same fluorescent competing ligand was used.  The differences in 
the different assay configurations should be a result of differences in the binding at 
equilibrium.   
 
Glucose-Dependent Fluorescence Responses 
The actual FA response to glucose concentrations (0-500 mg/dL, 50 mg/dL 
steps) for each of these assay configurations was determined experimentally.  All 
fluorescence measurements were obtained using black, flat-bottom, 96-well plates on a 
microplate reader (Tecan model F200) equipped with bandpass excitation filters (483 ± 
15.5 nm), emission filters (540 ± 25 nm) and polarizers (Tecan).  The G-factor was 
calculated using a known FA value for 1 nM fluorescein (0.018), and all subsequent runs 
used this adjustment factor to yield corrected data.   
Highly concentrated stock solutions of the individual assay components were 
prepared using TRIS.  Plates were quadruplicate loaded with the assay components, 
including glucose, and given time to reach equilibrium prior to analyzing in the plate 
reader at room temperature.  The actual glucose concentration was defined to be the 
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prepared concentration. Triplicate fluorescence scans were collected from each well of 
the microplate in the parallel and perpendicular directions. The actual FA value for each 
well was calculated by subtracting the TRIS background from each measurement, 
accounting for the differences in detector sensitivity to polarized light with the G-factor, 
and solving for FA with Equation 1.  The modeled and experimental glucose responses 
of each assay configuration are shown in Figure 30. 
 
 
Figure 30: (left) Modeled FA glucose response and (right) experimentally observed FA 
glucose response for the assay configurations in Table 5. The modeled curves for 1 and 2 
lay on top of each other and the error bars depict the standard deviation from the 
triplicate runs. 
 
 
The experimental response for each assay configuration displayed the trend that 
was predicted with the model.  For the same concentration of FITC-dextran, the assays 
using higher concentrations of ConA elicited a higher dynamic range across 
physiological glucose concentrations.  At 1 µM ConA and lower, there was effectively 
no response from the assay, which was predicted as shown in Figure 26.  In addition, a 
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large range of dextran concentrations (100 nM to 1 µM) for a given ConA concentration 
(100 µM) showed an effective, dynamic response. The dynamic range of the assay could 
be increased further by using concentrations of ConA up to 500 µM.  However, the 
solubility of the protein limited the highest concentrations of ConA to be 100 µM.  This 
extended dynamic range could be obtained if the fluorescent CL had a higher affinity to 
ConA, decreasing the required ConA concentration.   
Any assay has theoretical limits for what is possible.  To display the relative 
effectiveness of each assay to achieve its full potential, the percent optimization was 
determined for the individual mechanisms.  The percent optimization of the transduction 
mechanisms was defined as the expected change in anisotropy for each assay over the 
maximum possible change in anisotropy (0.4).  The percent optimization of the 
recognition mechanism was defined as the expected change in %CLB for each assay 
over the maximum possible change in %CLB (~45%).  To get the experimental 
sensitivity in the same units of percent optimized, the observed change in the anisotropy 
from 0 to 300 mg/dL was compared to the maximum possible expected change in 
anisotropy for a competitive binding assay to physiological glucose concentrations (0.4 * 
45% = 0.18).   Figure 31 displays the percent optimization of the transduction and 
recognition mechanisms as modeled for each assay and the percent optimization of the 
experimentally observed change in anisotropy. As the optimization of the recognition 
mechanism is increased, the experimental sensitivity increases as well.  This validates 
the ability to use the model to identify the optimal characteristics of the assay to 
maximize the individual mechanisms in order to maximize the experimentally observed 
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sensitivity to glucose.  By maximizing the degree to which each mechanism is 
optimized, we could achieve the ideal competitive binding assay for glucose sensing.   
Figure 31 suggests that we could see significant improvements in each of the 
mechanisms. 
 
 
Figure 31: Comparison of the level of optimization of the transduction and recognition 
mechanisms with the experimentally observed sensitivity. 
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Calibration of Optimized Sensing Assay 
One data set from the 1 µM FITC-dextran and 100 µM ConA assay was used to 
calibrate a predictive fit to the assay‟s glucose response using FA.  Equation 8, which is 
commonly used for fitting competitive binding assays, was used to fit the data.
127
  Using 
terminology of Findlay and Dillard, D is the FA response at infinite glucose 
concentration, A is the FA response in the absence of glucose, Glu is the glucose 
concentration, C is the inflection point on the calibration curve (IC50), and B is the slope 
factor.  This equation was solved by parameter optimization using the curve fitting 
toolbox in MATLAB.  The calibration data and the associated optimized fit using 
Equation 13 are displayed in Figure 32.   
 
 
      
     
  (
   
 )
  (13) 
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Figure 32: Experimental glucose-response for 100 µM ConA and 1 µM 4 kDa FITC-
dextran and the corresponding calibration fit.  (A = 0.0825, B =1.126, C = 160.4, D = 
0.03485).  The R-square value for this fit is 0.9951. 
  
 
 
Prediction Capabilities of Assay 
All collected data points for the 1 µM FITC-dextran and 100 µM ConA assay 
from 0 mg/dL and 300 mg/dL glucose concentrations were used to determine the error 
associated with the prediction.  This included 7 calibration data points and 20 prediction 
data points.  The actual versus predicted glucose concentrations for the 1 µM FITC-
dextran and 100 µM ConA assay were then plotted in Figure 33 for further analysis.  
Linear regression was also performed on the predictive data to give a standard error of 
prediction. 
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Figure 33: Predicted glucose vs. actual glucose for the FA competitive binding assay 
using 1 µM 4 kDa FITC-dextran and 100 µM ConA. 
 
 
The assay displayed a prediction error of 22.4 mg/dL.  This is the convolution of 
the pipetting, recognition, transduction, and detection errors within the system.  
Therefore, the standard error of prediction demonstrates an upper limit to the recognition 
error associated with ConA in a glucose-based sensor, and could be shown to be even 
lower.  For example, the detection error could be decreased by using a 
spectrofluorometer system equipped with polarizers that have a higher extinction ratio 
(e.g. Glan-Thompson) than the sheet polarizers used in fluorescent microplate readers.  
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Nevertheless, this level of predictive error shows that the lectin, ConA, can be quite 
effective at predicting glucose concentrations in a sensor that has independently been 
optimized with regards to its recognition and transduction mechanisms.     
 
Adjusted Model with the Relative Quantum Yield  
While the model is validated to be capable of predicting trends and optimized 
regions, there do exist a few differences between the experimental data and the model 
that are important to note.  The experimentally determined FA is lower than the modeled 
FA values which could be explained by local fluorophore motion allowed by the linkage 
between the fluorophore and the ligand.
128
  This shift in FA could also be seen if the 
dextran structure and the dextran/ConA complex were not perfectly spherical.  The 
ellipsoidal nature of the bound and unbound dextran would result in a shorter rotational 
correlation lifetime, decreasing the observed FA.  Either way, the change in FA is 
similar to those predicted. 
Another difference between the modeled and experimental results is the upwards 
shift of the FA values relative to the baseline at 500 mg/dL glucose for assays with 
higher ConA concentrations.  This shift could be attributed to an increase in viscosity 
from the high protein concentrations.   As seen in Equation 7, the rotational correlation 
lifetime of a fluorophore is directly proportional to the viscosity of the solution in which 
it resides.  As slight increases in viscosity would be expected at 100 µM ConA, the FA 
of the fluorescent molecules within the sample could increase accordingly.   
 89 
 
The slight difference between the predicted change and actual change to glucose 
could potentially be explained via changes in the fluorescence lifetime upon ConA 
binding to the 4 kDa FITC-dextran.  In this original model, the quantum yield and the 
lifetime of FITC-dextran were assumed to remain constant upon binding.  To test this 
assumption with regards to the predicted anisotropy response, the fluorescence lifetime 
of the free and bound states of 4 kDa FITC-dextran was experimentally determined.   
 
 
Figure 34: Fluorescence lifetime studies of 1 µM FITC-dextran and 1 µM FITC-dextran 
with 100 µM ConA.  The IRF is from the pulsed LED. 
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Fluorescence Lifetime Studies 
These fluorescence lifetime studies were performed using a stroboscopic 
technique on a TM-200 PTI spectrofluormeter in the Materials Characterization Facility 
(MCF) at Texas A&M University.  This spectrofluorometer was equipped with a 460 nm 
LED and a R928 photomultiplier tube collecting emission at 520 nm.  Figure 34 shows 
the fluorescence decays of 1 µM FITC-dextran (alone) and 1µM FITC-dextran paired 
with 100 µM ConA.  The fluorescence decay of the FITC-dextran solution was fit with a 
single fluorescence lifetime.  Then, the solution with FITC-dextran and ConA was fit 
with two fluorescence lifetimes where one was fixed to be lifetime of the FITC-dextran 
solution, presumably the lifetime of the free population. 
The fits generated a single 3.897 ns lifetime for the 1 µM FITC-dextran with a 
chi-squared value of 1.297.  For the combined assay, it generated a 3.897 ns lifetime and 
a 1.73 ns lifetime for the free and bound populations with a chi-squared value of 1.097.  
The fit for the combined assay showed at t=0 showed ~66% with the free lifetime and 
34% with the bound lifetime, which agreed with the predicted competitive binding 
modeling for this assay at 0 mg/dL glucose.  The modeled anisotropy response was then 
adjusted to account for the effect of this change with regards to an adjusted bound 
anisotropy and an adjusted fractional intensity from the bound population.   Table 6 
shows the predicted anisotropy of 4 kDa FITC-dextran bound to ConA using the initial 
model that assumes the lifetime is unchanged upon binding to ConA (~4 ns) and the 
adjusted model that accounts for the change in lifetime (1.7 ns) using Equation 6. 
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Table 6: Initial modeled FA and Adjusted modeled FA to account for the change in 
fluorescence lifetime of the bound population. 
Competitive Ligand (CL) Initial FA bound to ConA Adjusted FA bound to ConA 
4 kDa FITC-dextran 0.382 0.392 
 
 
If the quantum yield of the fluorescent ligand changes upon binding to ConA, 
then the total fluorescence intensity coming from the samples should be glucose 
dependent.  The fractional fluorescence intensity that comes from the bound population 
is no longer equal to the percent of the fluorescent ligand that is bound.  Instead, it is 
related to the total fractional fluorescence intensity that can be expected due to the 
glucose binding.   Equation 14 was then used to describe the total fluorescence intensity 
(Ftot) of the 1 µM FITC-dextran and 100 µM ConA assay after adjusting for the change 
to lifetime upon binding (RQY = relative quantum yield).  The RQYbound was defined by 
Equation 15, and the RQYfree is defined to be 1.  The %CLB(glu) was used from the 
model like before.  To determine whether this change in fluorescence intensity was 
reasonable, it was compared with experimental data and shown in Figure 35.  The total 
fluorescence signal from each well in the microplate was calculated by summing the 
parallel and perpendicular intensities.   
 
                                                    (14) 
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Figure 35: Total fluorescence intensity from the 1 µM FITC-dextran and 100 µM ConA 
assay as a function of glucose.  The initial model assumed no change in lifetime upon 
binding.  The adjusted model accounted for changes in the fluorescence lifetime.  
 
 
The initial model assumes that the fluorescent intensity is independent of binding 
(normalized intensity =1).  The adjusted model accounts for the relative change in 
quantum yield to generate the normalized fluorescence intensity (Figure 35).  The 
experimental data more accurately follows the adjusted model when compared to the 
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initial model.  Each data point is a uniquely loaded well, and the large standard deviation 
can be attributed to pipetting error.  
 
Adjusted Model 
After confirming that the fluorescence does seem to be increasing across 
physiological glucose concentrations, an adjusted model of the anisotropy can then be 
generated.  Equation 16 is the adjusted model for the anisotropy in terms of the adjusted 
fluorescence contributions from the free and bound populations and the adjusted 
anisotropy of the bound populations.  The Ftot was used as described in Equation 14.  
The comparison of this model with the original model is shown in Figure 36.   
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Figure 36: Initial and adjusted models of the glucose response for the 1 µM FITC-
dextran and 100 µM ConA assay.  The initial model assumed no change in lifetime upon 
binding.  The adjusted model accounted for changes in the fluorescence lifetime. 
 
 
When compared to the experimental, glucose-dependent changes to the 
anisotropy (~.035), the adjusted model does more accurately predict the change (.035) 
than the initial model (.060).  However, it is important to note that the trend is similar.  
This is due to the fact that the decrease in fluorescent lifetime increases the expected 
anisotropy of the bound population but decreases the percent of the fluorescence that 
comes from the bound population also (Equation 16).   This combination limits the effect 
that lifetime changes have on the expected anisotropy response, allowing the 
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aforementioned assumption to remain relatively valid when choosing an appropriate 
fluorophore for these studies.   
This anisotropy response could be further improved by using a fluorophore that 
undergoes less of a change in lifetime upon binding to ConA.  However, without a priori 
knowledge of the fluorescence lifetime upon binding, the initial assumption that the 
fluorescence lifetime is unchanged upon binding can allow the user to identify an 
appropriate fluorescent CL.  For this work, an assay based on 4 kDa FITC-dextran and 
ConA can be optimized using the initial model, and experimental data from the 
optimized assay of 1 µM 4 kDa FITC-dextran and 100 µM ConA elicits an appreciable 
change in anisotropy.    
 
Model of Previous ConA-Based Assays 
Now that the model has been validated, it can be used in an attempt to describe 
the previous work with ConA.  This work will primarily use the model for the 
recognition mechanism to model two distinct assays.  The first uses a fluorescent ligand 
that displays a typical association constant for monovalent sugars (Ka = 10
-3 
M
-1
).
126
  The 
other assay uses typical association constant for multivalent presentation of sugars on a 
dendrimer (Ka = 10
-6 
M
-1
).
61,129
  Concentrations of each component in the competitive 
binding assays are used to maximize the binding while staying below the solubility limit 
of ConA (100 µM).   
One assumption for this model was that the binding is monovalent.  
Monosaccharides have proven to remain stable with ConA in free solution.  However, 
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multivalent sugars (like the dendrimer modeled here) show aggregation and precipitation 
over time.  To be able to use this model to describe the equilibrium binding as a result of 
aggregation, it is run at different time points to account for the time-dependent 
aggregation.  To account for the level of aggregation in those runs, the affinity is 
changed accordingly.  It is well known that when a single protein binds to two ligands 
simultaneously, it‟s apparent affinity increases significantly due to chelation.  Time-
dependent aggregation can then be tracked in this model using increasing affinities.  
Therefore, to account for this in our model for steady-state equilibrium binding, we ran 
the glucose response for the same assay but with an increasing affinity between the 
fluorescent ligand and ConA.   
 
 
Figure 37: Predicted glucose-dependent binding for assay that uses a competing ligand 
that presents a single glucose residue. 
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Figure 37 shows the recognition mechanism of an assay that uses a competing 
ligand that presents a single monosaccharide that binds to ConA.  Because of the low 
affinity and the solubility limit of ConA, the ConA concentration cannot be high enough 
to allow for significant binding between ConA and the competing ligand.  Therefore, 
increasing glucose concentrations do not significantly change the %CLB (competing 
ligand bound).  This displays the primary reason that groups use multivalent ligands as 
competitors: to increase the association constant in order to lower the required ConA 
concentration so the recognition mechanism can be optimized.   
Figure 38 shows the recognition mechanism of an assay that uses a competing 
ligand that presents multiple monosaccharides on its surface (like a glycosylated 
dendrimer).  The increased association constant allows the assay to be optimized (blue 
diamonds) and significantly respond to physiological glucose concentrations.  However, 
as the affinity increases due to aggregation and chelation, the competitive binding shifts 
keeping ConA bound to the competing ligand over the same glucose range (red square, 
green triangle, gray x‟s).  Eventually, the assay does not respond to physiological 
glucose concentrations.  It could be reversed, but it would require significantly higher 
glucose concentrations than what is seen in the body.   
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Figure 38: Predicted glucose-dependent binding for assay that implements a multivalent 
competing ligand.  The time-dependent aggregation increases the affinity and changes 
the glucose response. 
 
 
These results for the recognition mechanism using the monovalent and 
multivalent competing ligand were combined with an ideal fluorescence transduction 
mechanism to show what one would measure for the different assays.   With a modeled 
fluorescence anisotropy that changes from 0.05 to 0.35 upon binding to ConA, Figure 39 
shows the responses for the monovalent ligand (black) and the multivalent ligand (gray).  
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Figure 39: Predicted glucose responses over time for assays that use either monovalent 
(black) or multivalent (gray) competing ligands. 
 
 
Because the monovalent ligand does not allow for extended aggregation between 
multiple components, the affinity stays constant over time and the resulting anisotropy 
response does as well.  However, because the affinity is weak, the sensitivity of the 
response is low because the recognition mechanism is not capable of being properly 
tuned.  On the other hand, the increased affinity of the multivalent originally allows the 
recognition mechanism to be properly tuned, as seen by the very sensitive anisotropy 
response (gray).  However, as time-dependent aggregation occurs, the increasing affinity 
changes the assay to require higher glucose concentrations to induce competitive 
binding.  This effectively decreases the assay‟s sensitivity to physiological glucose 
concentrations over time and causes it to lose repeatability/reversibility.   
This describes the apparent tradeoff between sensitivity and repeatability that is 
typical of the ConA-based competitive binding assays found in the literature. Using 
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traditional approaches, the fluorescence assay cannot achieve a stable, optimized 
recognition mechanism in free solution.  Monovalent competing ligands show a non-
optimized recognition mechanism, but the glucose response is constant over time.  On 
the other hand, multivalent competing ligands allow for high initial sensitivities due to 
optimized recognition mechanisms, but aggregation-induced increases in affinity display 
changes in the fluorescent response over time.  To avoid this trade-off in free solution 
and display the full potential of such an assay, higher affinities must be generated while 
preventing this aggregation over time.  If such an assay were able to be made, it is 
expected generate a response like the red columns in Figure 40. 
 
 
Figure 40: Assays that achieve higher affinities without allowing for aggregation with 
ConA are expected to display repeatability (red). 
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Defining Ideal Assay Characteristics 
These models for the recognition and transduction mechanisms can be used to 
identify a ligand that can best optimize the ConA-based competitive binding assay.  
Because of the linear nature of the fluorescence anisotropy, it is essential for both 
mechanisms to be optimized.  Figure 41 shows four hypothetical cases for different 
levels of optimization for the recognition and transduction (fluorescence) mechanism.  
Only when both are optimized is the measured sensitivity high.  
 
 
Figure 41: Hypothetical cases that show the relationship between the level of 
optimization of the fluorescence and recognition mechanisms and the expected 
experimental sensitivity of the assay. 
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Recognition Mechanism 
The 2D-sensitivity plots can be useful in identifying regions of interest.  Figure 
42 shows the recognition sensitivity of an assay with 500 nM, fluorescent ligand with a 
zone circled with a dotted line.  Obviously, the goal is to be in the dynamic portion of 
this graph (the dark red).  Because ConA is insoluble above 100 µM, the assay requires a 
competing ligand to be chosen that has an affinity between 10
5
 M
-1
 and 10
7
 M
-1
.  It is 
important to note that the ConA could eventually be labeled with a fluorophore for 
FRET studies.  Therefore, high ConA concentrations could result in significant 
absorption from the acceptor fluorophore.  The higher affinities (in the tolerable zone) 
allow lower ConA concentrations to be used. 
 
 
Figure 42: Recognition sensitivity of 500 nM fluorescent ligand.  Within the dotted line 
is the ideal region for the assay to stay below the solubility limit of ConA. 
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Transduction Mechanism 
The 2D map for the transduction sensitivity of an anisotropy based assay is 
shown in Figure 43 with a desired region circled in a dotted white line.  While there are 
regions on this graph that display slightly higher sensitivities than those in the dotted 
line, these are relatively impractical.  For this ligand to compete with glucose for the 
binding site on ConA, it must at least have a glucose or mannose residue, and for it to be 
fluorescent it must have a fluorophore.  So, a ligand will most likely have a MW of at 
least ~600 Da, and probably closer to 1 kDa.  For this range of MWs, a fluorophore with 
a lifetime of 2-15 ns is expected to display an ideal sensitivity with regards to the 
fluorescence anisotropy transduction mechanism.     
 
 
Figure 43: Transduction sensitivity using fluorescence anisotropy with the optimized 
zone circled in the white dotted line.  This would display a MW of ~1 kDa and a 
fluorescence lifetime of 2-15 ns.    
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Figure 44: Schematic representation of the transduction mechanism for a FRET assay 
based on competitive binding with ConA. 
 
 
Ultimately, this assay would be well-suited to employ FRET as the transduction 
mechanism to track the binding (Figure 44).  This would allow the assay to be implanted 
and interrogated through a highly scattering environment like tissue.  The goal of such 
an assay would be to maximize the difference in the FRET efficiency between the bound 
and the free populations.  Assuming that the assay is configured in a way to avoid 
diffusion effects on the FRET efficiency, the efficiency of the unbound population can 
safely be assumed to be low.  Therefore, to create a 2D sensitivity map of the 
transduction mechanism for FRET, the FRET efficiency of the bound population can be 
modeled.  This efficiency is described with Equation 17, showing that it is a function of 
the distance between the donor and the acceptor (r) and the Fӧrster radius of the FRET 
pair that‟s chosen (R0).  This Fӧrster radius is a value that is defined by the FRET pair 
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that is chosen and is associated with the spectral overlap of the donor and acceptor 
fluorophores.  
 
 
   
 
  (   ⁄
)
  (17) 
 
This equation can be solved for a given Fӧrster radius and a given distance 
between the donor and nearest acceptor fluorophore. Figure 45 displays the collective 
solutions to all possible combinations for Fӧrster radius and distances from 1-10 nm.  
The blue zone indicates an area that is expected to show low FRET efficiency.  The red 
zone indicates an area that is expected to show high FRET efficiency.  It is effectively 
when the distance between the donor and acceptor is shorter than the Fӧrster radius of 
the FRET pair.   
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Figure 45: Efficiency of the FRET transduction mechanism upon binding with the target 
zone circled in the white dotted line.   
 
 
The dotted line indicates desirable characteristics for the ConA-based 
competitive binding assay to maximize the sensitivity when using FRET as the 
transduction mechanism.  These types of Fӧrster radii can be achieved by the choice of 
the donor and acceptor that are used in the assay.  It is the average distances between the 
donor and acceptor fluorophores upon binding that has been the problem to date.  Many 
of the competing ligands that have been paired with ConA are so large that, even upon 
binding to one of the moieties, the fluorophores are too far apart to undergo energy 
transfer.  The traditionally used multivalent ligands are expected to have this problem 
(70 kDa dextran is ~10 nm in diameter) and could show an average distance as indicated 
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by the black dot.  The goal for the transduction mechanism is to identify a ligand that 
can allow the distance between the donor and acceptor to be within the Fӧrster radius 
upon every binding event.  
This modeling of each individual mechanism shows that a fluorescence 
anisotropy ConA-based assay would be optimized with a fluorescent ligand that has a 
MW of ~1 kDa, a fluorescence lifetime of ~5 ns, and an affinity to ConA of ~10
6
 M
-1
.  A 
FRET assay does not depend on the MW of the ligand, but would require the average 
distance between the donor and acceptor to be significantly shorter than the Fӧrster 
radius of the FRET pair. A fluorescent ligand that meets these requirements, does not 
allow for aggregation to occur and is either neutral or negatively charged is given the 
term „smartly-designed fluorescent ligand‟ for a ConA-based glucose sensing assay. 
 
Conclusions 
This chapter displayed models of the recognition and transduction mechanisms 
of the ConA-based competitive binding assay, and generated 2D sensitivity maps for the 
variables in the assay.  These models were validated with experimental results with 4 
kDa FITC-dextran as the fluorescent ligand.  An assay based on this ligand was 
optimized and developed into a fluorescence anisotropy sensor for glucose 
concentrations.     
Unlike enzymatic assays that are directly dependent on the rates of diffusion, 
affinity-based assays are much less sensitive to changes in diffusion rates.  Therefore, 
these affinity-based assays have the potential to be optimized in free solution before 
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encapsulating the assay into a deliverable form (e.g. microcapsules).  As a result, this 
work displays the capability for models to play an important role in the development of 
implantable sensors based on affinity binding.  Accordingly, the validated model was 
then used to describe previous attempts at the ConA-based sensor.  We identified that the 
primary barriers to ConA sensors are (1) the apparent obstacle of needing to use 
multivalent ligands for affinity enhancement even though they aggregate with ConA in 
free solution causing irreversibility and (2) the inability for the average distance between 
the donor and acceptor fluorophores of the bound population to be within the Fӧrster 
radius of the chosen FRET pair.   
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CHAPTER IV 
SMARTLY-DESIGNED FLUORESCENT LIGAND FOR CONA-BASED ASSAYS 
 
Introduction 
In the last chapter, we introduced the requirements for a dynamic competitive 
binding assay in which the fluorescence of the competing ligand is tracked with 
anisotropy.  Briefly, this required the competing ligand to have an affinity that is higher 
than what is typically seen for monosaccharides.  To date, this has been achieved by 
implementing fluorescent ligands that presented multiple monosaccharides on a single 
ligand (e.g. dextrans & dendrimers).  This multivalent presentation is known to increase 
the apparent affinity to a receptor through proximity effects.
129,130
  However, groups 
have continued to report visual aggregation due to extensive crosslinking, resulting in 
the lack of reversibility of the assay in free solution.  This aggregation problem of 
ConA-based sensors has been identified as their primary barrier, and we have proposed 
that the irreversibility is due to the aggregation arising from multivalent ligands being 
paired with multivalent receptors.  Ever since the original assay was introduced in 1982, 
there has been a tradeoff between long-term repeatability/reversibility and initial 
sensitivity in free solution.   
 In this chapter, we introduce a smartly-designed fluorescent ligand that is 
engineered to display the ideal properties for the recognition and transduction 
mechanisms of a ConA-based assay.  This ligand displays the unique capability to 
achieve the required affinity without allowing for aggregation, and it can be effectively 
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inhibited with glucose and mannose.  This smartly-designed fluorescent ligand is 
synthesized, characterized, and implemented into both an anisotropy based assay and a 
FRET-based assay for glucose sensing. 
 
 
Types of Affinity Enhancement 
While the binding of monosccharides to lectins is generally a weak interaction with a 
dissociation constant of ~mM, nature employs different strategies to increase the affinity 
of these events.
130
  One method is to increase the number of monosaccharides that are 
presented on a molecule.  While ConA only binds to a single monosaccharide on the 
structure, the high local concentration of monosaccharides makes the dwell time longer 
a
nd causes the affinity to appear higher.  As previously mentioned, groups have 
a
ttempted to achieve the higher affinities that are required for ConA-based glucose 
sensing by using molecules that use this approach.  However, as shown in Chapter 4, this 
c
an lead to aggregation over time which results in a lack of reversibility.     
Another approach that nature uses to achieve increased affinities to a given lectin is 
b
y using subsite binding.
129
  This approach has an extended binding site near the primary 
binding site on the lectin for specific sugar moieties.  Because additional interactions are 
made between the sugar and the full binding site, the affinity is increased.  The 
difference between proximity effects and subsite binding are shown in Figure 46.   
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Figure 46: Types of affinity enhancement with ConA.  (left) Competing ligands that 
employ proximity effects lead to aggregation with ConA.  (right) Chelation through 
subsite binding can potentially avoid aggregation if a single ligand is presented. 
 
 
ConA’s Full Binding Site 
Adjacent to ConA‟s primary binding site is an extended pocket that has been 
shown to form additional hydrogen bonds to the core trimannose of N-linked glycans 
(trimannose).
131,132
  Groups have performed X-ray crystallography studies with ConA 
and various ligands.  The crystallography data was obtained for ConA‟s interaction with 
methyl-alpha-mannose and the core trimannose (1CVN and 5 CAN), and the relative 
orientations of the ConA‟s binding to each ligand was determined using the Ligand-
Interaction tool in the Maestro software (v. 9.5).
131,133
  Figure 47 shows the amino acids 
(black dots) in the crystallography structure that are within a distance that is capable of 
forming hydrogen bonds.  These amino acids display the extended binding site to which 
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the core trimannose binds.  This shows that ConA forms hydrogen bonds with each 
mannose group of the trimannose, which should increase the affinity without leaving 
moieties for additional ConA to bind.  It also shows that the trimannose could compete 
with the monosaccharide for binding to a ConA subunit because they both bind to the 
primary binding site. 
 
 
Figure 47: Comparison between carbohydrate binding to the primary binding site of 
ConA and the full binding site of ConA, using the crystal structures from ref. 131 & 133.  
Black dots: amino acids capable of forming of hydrogen bonds with the sugar (3.5 Å). 
 
 
Aggregation Studies 
To explore whether the interaction of ConA with the core trimannose leads to 
aggregation in free solution, dynamic light scattering (DLS) measurements were 
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performed.  This interaction was compared to the interactions between ConA and other 
high-affinity ligands that are commonly used in ConA-based assays.  Dextran, dendrimer 
and trimannose were added to separate cuvettes of ConA solutions in TRIS buffer, and 
allowed to interact for 12 hours at 22 deg C.  The TRIS buffer was 10 mM TRIS, 1 M 
NaCl, 1 mM CaCl2, 1 mM MnCl2, at pH 7.4.  The dextran was 2 MDa and used as 
received from Sigma.  The dendrimer was a generation three glycosylated dendrimer (24 
terminal amines, 24 terminal glucose residues) were used as provided by Dr. Eric 
Simanek (Texas Christian University).   
Dynamic light scattering was then used to examine the average size of particles 
formed in comparable solutions.  As controls, solutions of the individual components 
were also scanned to determine the particle size in the absence of aggregation.  The final 
concentration was 3 µM for the competing ligand and 3 µM for ConA.  Negative 
controls were run for each competing ligand (3 µM) without ConA present.  ConA was 
also independently added to a separate control cuvette (3 µM).  All solutions were in 
TRIS buffer and were filtered prior to combining the solutions.  After 12 hours, the 
solutions were mixed to allow for the re-suspension of any settled material and dynamic 
light scattering studies were performed.  The reported data is the average particle size as 
determined by percent-volume.    
Figure 48 shows that the average size of the particles is much larger after 12 
hours for solutions of ConA paired with dendrimer and dextran, indicating that ConA 
and the high-affinity ligands have already formed extensive aggregates.  In comparison, 
the average size of particles in the solution that contains trimannose and ConA has not 
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increased in size, indicating that, if binding occurred, a single presentation of trimannose 
significantly decreases the extent of aggregation and potentially prevents it completely.   
 
 
Figure 48: Average particle size of solutions with ConA and various high-affinity 
ligands.  The error bars indicate the standard deviation of 3 different samples. 
 
 
Smartly-Designed Fluorescent Ligand Concept 
Figure 49 shows a modular representation of a fluorescent ligand that is 
composed of (A) a sugar moiety portion that can bind to ConA and (B) a fluorophore.  
The working hypothesis is that the full potential of ConA assays (in terms of the 
recognition mechanism) can be shown if the fluorescent ligand can display the higher 
affinity without aggregating with ConA.  We just showed that the core trimannose does 
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not aggregate with ConA, and the crystallography information that suggests the affinity 
should be increased due to the subsite binding.  Therefore, we attempt to generate a 
smartly-designed fluorescent ligand where the (A) portion of the fluorescent ligand is 
based on a single presentation of the core trimannose.  
 
 
Figure 49: Recognition (A) and transduction (B) components of a fluorescent competing 
ligand.  A smartly-designed fluorescent ligand would be engineered to maximize both 
mechanisms. 
 
 
Preparation of Smartly-Designed Fluorescent Ligand 
Synthesis of APTS-Mannotetraose 
The goal, therefore, is to generate a fluorescent ligand that displays the core 
trimannose.  Ideally, this would result in a molecule that had a fully-preserved 
trimannose group and a single fluorophore.  Therefore, the commonly used periodate 
oxidation method to generate carbonyl groups on a polysaccharide for fluorophore 
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attachment was not appropriate.
134
 This would destroy the ring mannose moieties 
required for binding to ConA‟s full binding site and could introduce several fluorophores 
to a single glycan.   
Reductive amination is a more controlled method that has been used to label 
glycans for subsequent chromatographic or electrophoretic separation and identification 
of the glycans.
135-138
  By using an amine-bearing fluorophore, this method introduces a 
single label at the reducing termini of the glycan.  This causes the reducing sugar of the 
glycan to be acyclic but leaves the remaining sugars of the glycan in their cyclic, 
unaltered form to be recognized by receptors.
139
 Thus, we used the trimannose bearing 
mannotetraose to maintain the trimannose structure after conjugation.  
8-Aminopyrene-1,3,6-trisulfonic acid (APTS) was chosen as the amine-bearing 
fluorophore to attach to the mannotetraose.  APTS is a water-soluble fluorophore whose 
fluorescence is independent of pH over a wide range.  It has been used to label an 
unknown population of glycans enzymatically cleaved from glycoproteins via reductive 
amination to facilitate their separation via capillary electrophoresis due to its three 
negative charges per fluorophore at neutral pH.
136
  Because ConA‟s isoelectric point is 
around 5, these negative charges also minimize non-specific electrostatic interactions 
between the fluorescent ligand and ConA at physiological pH.   
Mannotetraose was purchased from Dextra Laboratories and 8-Aminopyrene-
1,3,6-trisulfonic acid (APTS) was provided by Dr. Gyula Vigh.  Mannotetraose (0.9 mg, 
1.35x10
-6
 mol) was mixed with 13.5 μL of 1 M APTS (1.35x10-5 mol) prepared in 15% 
acetic acid aqueous solution.  Then, 54μL of 15% acetic acid aqueous solution was also 
 117 
 
added into the mixture.  The acidic environment promotes the ring-opening of the 
reducing terminus of mannotetraose.  The reaction mixture was stirred for 5 minutes at 
room temperature.  Then, 13.5μL of 1M sodium cyanoborohydride (NaBH3CN, 1.35x10
-
5
 mol) in THF was added into the reaction and had it stirred for 14 hours at room 
temperature.  The schematic is shown in Figure 50.  Sodium cyanoborohydride is a 
reducing agent that converts the Schiff base into the stable APTS-mannotetraose (APTS-
MT) conjugate.  APTS-glucose and APTS-maltotriose were also synthesized using this 
method.   
Note that this reaction step should be performed in a properly ventilated fume-
hood as hydrogen cyanide gas (toxic) can be liberated from the solution.  Other groups 
have shown that 2-picoline borane is another effective reducing agent for the reductive 
amination of glycans with fluorophores.
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This type of reaction can be performed to conjugate the glycan to other 
fluorophores as well.  Most often, these fluorophores have an aromatic amine to 
maximize the efficiency of the reaction over a shorter time.
135,138
  These aromatic amines 
can be deprotonated even under the acidic conditions for the reductive amination. 
Groups have also used fluorophores that present hydrazides and thiosemicarbazides in 
non-reducing conditions.
139,141
  This allows the reducing sugar to return to the cyclic 
form and still be attached via the hydrazide.  This is more stable than the Schiff base, but 
it is not as stable as the conjugate that has been reduced.  
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Figure 50: Synthesis of APTS-MT via reductive amination to form a ligand with a 
single fluorophore and a single trimannose moiety. 
 
 
 
 119 
 
Separation with HILIC Chromatography 
 Following the reductive amination synthesis, the crude product was purified by 
hydrophilic interaction liquid chromatography (HILIC) and identified via its change in 
absorbance.  An HPLC system containing a solvent delivery module Model 126, an auto 
injector Model 508 and a photodiode array detector Model 168 operating under 32 Karat 
software control (Beckman-Coulter, Fullerton, CA) was used for reaction monitoring. 
HILIC separations were obtained on a 4.6 mm I.D., 150 mm long analytical column 
packed with a 3 µm HILIC stationary phase (Phenomenex, Torrance, CA).  Solvents 
used were A: 100% water; B: 5% water, 95% acetonitrile both containing 10 mM 
ammonium formate, 5mM formic acid, pH 9. Isocratic: 80 %B, 10 min.  The 
chromatogram is shown in Figure 51.  
 
Confirmation with Mass Spectrometry 
Mass spectra of this sample were acquired in negative ion mode using an MDS 
SCIEX (Concord, Ontario, Canada) API QStar Pulsar.  Sample was dissolved in 
(methanol) and electrosprayed using ionspray (needle) at- 4.5 kV.  Sheath gas and 
curtain gas flow rates were set to 40 and 20 psi, respectively.  The sample flow rate was 
7 µl/min.  Multiply charged ions were detected. 
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Figure 51: Separation of (A) APTS free dye from (B) APTS-MT product using HILIC 
chromatography.  Inset: Comparison of the absorption spectra. 
 
 
Fluorescence Characterization of APTS-MT 
Excitation/Emission/Intrinsic Anisotropy 
The final concentrations of the APTS-MT and APTS-glucose were determined 
using absorbance spectroscopy with the extinction coefficients found in the literature for 
APTS.
142
  This was performed on a Cary-instrument using the appropriate corrections.  
Steady state fluorescence and intrinsic anisotropy measurements were performed on a 
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Fluorolog-3 from Horiba Jobin Jvon.  For steady-state fluorescence measurements, 
solutions of 100 nM APTS and APTS-MT were made to avoid inner filter effects in 
TRIS buffer.  Excitation and emission scans were performed to determine the 
fluorescence spectra of APTS-MT.     
Intrinsic anisotropy measurements were performed by adding the fluorescent 
molecule of interest in a 50% glycerol solution at a concentration of 100 nM and setting 
the temperature to 5 deg C.  This effectively slowed the rotation of our fluorescent 
molecules to negligible amounts (while in the excited state) which can allow the steady-
state anisotropy value to be equivalent to the intrinsic anisotropy.  Quartz cuvettes were 
used to avoid birefringence effects on the measured anisotropy.  The anisotropy was 
recorded by collecting the emitted fluorescence at 520 nm with 5 nm bandpass.  The G-
factor was calculated for each sample.  Ten measurements were taken for each sample, 
and the recorded anisotropy was the average of those measurements.  Figure 52 shows 
the results of this steady-state fluorescence characterization for APTS and APTS-MT.  
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Figure 52: Fluorescent properties of APTS (top) and APTS-MT (bottom).  Note that the 
excitation and emission shifts approximately 20 nm. 
 
 
The fluorescence of unconjugated APTS shows an excitation maximum at ~425 
nm and an emission maximum at ~505 nm.  After conjugation, the APTS-MT smartly-
designed fluorescent ligand shows an excitation maximum at ~460 nm and an emission 
maximum at~520 nm.  APTS-glucose shows similar spectra to APTS-MT.  All spectra 
are corrected for the instrument response.  This shift in the fluorescence spectra upon 
conjugation is due to the reorientation of the electron density of the pyrene backbone, 
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and the shift in absorbance has commonly been used to identify via unique populations 
during chromatography.  The fluorophore shows a relatively high stokes shift of 
approximately 70 nm, which allows for a large band of fluorescence wavelengths to be 
collected to improve without problems arising from scattered light. 
Regarding the steady-state anisotropy, the fluorophores are effectively 
immobilized for the given fluorescence lifetime under these conditions.  The intrinsic 
anisotropy is relatively stable for both conjugates near the excitation maximum, with a 
value of ~0.3.  If a longer-lifetime fluorophore was used, higher viscosities and lower 
temperatures would need to be used.   
 
Fluorescence Lifetime and Dynamic Anisotropy 
The fluorescence lifetime and dynamic anisotropy data were collected using a 
DeltaFlex time correlated single photon counting system from Horiba that was equipped 
with a 482 nm DeltaDiode pulsed source.  The emission was set to 520 nm with the slit-
width allowing 8 nm bandpass.  A 500 nm high-pass filter was used to avoid any 
scattered excitation light.  The effect that ConA binding has on the rotational correlation 
lifetime of APTS-MT was studied using a solution of 200 nM APTS-MT with and 
without 1 µM ConA present.  Quartz cuvettes were used to avoid birefringence effects 
on the anisotropy measurements.  Neutral density filters were used to adjust the 
fluorescence intensity to allowable levels.  For fluorescence lifetime measurements, the 
excitation polarizer was in the vertical orientation and the emission polarizer was set to 
the magic angle (~54.7°).  Data was taken until the maximum counts were 10,000.  
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Silica particles in DI were used as the sample to scatter light to determine the pulse-
shape of the 482 nm source.  For dynamic fluorescence anisotropy measurements, the 
fluorescence emission was collected in parallel and perpendicular configurations until 
the difference of the first point was 15000 counts.    The fluorescence intensity decays 
were analyzed with the Decay Analysis Software (v. 6.6) from Horiba, and fits were 
used according to the expected distribution in the solution. The dynamic anisotropy 
decays were analyzed by using a reconvolution algorithm to determine the best-fit 
rotational correlation lifetimes.  The fluorescence lifetime decay is shown in Figure 53, 
which displays a single exponential decay of ~5.3 ns.  The dynamic anisotropy curves 
with the modeled rotational correlation lifetimes are shown in Figure 54.     
 
 
Figure 53: Fluorescence decay curve of APTS-MT, showing a lifetime of ~5.3 ns. 
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Figure 54: Dynamic anisotropy and rotational correlation lifetimes of APTS-MT with 
and w/o ConA 
 
 
The reconvolution algorithm for the dynamic anisotropy displays rotational 
correlation lifetimes for the free and bound APTS-MT at ~1 ns and ~20 ns.  The relative 
ratio between r1 and r2 is the relative fluorescence intensities between the two 
populations when the sample is initially pulsed.  Therefore, if you assume that the 
quantum yield does not change upon binding and the solution is at steady-state binding, 
this is a measure of the relative concentrations of the APTS-MT in solution.  These 
values suggest that at 1 µM, approximately 50% of the APTS-MT is bound to ConA, 
which is approximately what is expected with regard to the affinity.   
These rotational correlation lifetimes are a measure of how fast the fluorescent 
particle is rotating in free solution.  It would be ideal, therefore, for the fluorescence 
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lifetime to be between the rotational correlation lifetime of the bound fluorescent ligand 
and the free fluorescent ligand (Figure 55) to maximize the change of in the steady-state 
anisotropy.   
 
 
Figure 55: Schematic of the relationship between rotational correlation lifetimes and 
fluorescence lifetime.  The optimal fluorescent lifetime is between the rotational 
correlation lifetimes of the bound and free fluorescent ligand.   
 
 
Binding Characterization 
A filter-based fluorescence microplate reader that was equipped with polarizers 
and the appropriate fluorescence filters for APTS was used to perform binding studies.  
The equilibrium-binding between ConA and APTS-MT was performed by loading a 
microplate with serial dilutions of ConA and the same concentration of APTS-MT (500 
nM).  The plate was allowed to reach equilibrium at room temperature (22 deg C), and 
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scans were performed in the perpendicular and parallel directions.  Background was 
subtracted from each value.  The G-factor was calculated from the fluorescence 
anisotropy for free APTS-trimannose at a value of 0.03, and this G-factor was used for 
the remaining experiments.  Assuming the change in fluorescence lifetime upon binding 
to ConA to be negligible, the ConA-dependent anisotropy was calculated and shown in 
Figure 56.  These results were fit with a Boltzmann curve to determine the association 
constant to be 5.61*10
6 
M
-1
. 
 
 
Figure 56: Fluorescence anisotropy response of 200 nM APTS-MT to increasing 
[ConA].  The Ka was determined to be 5.61*10
6
 M
-1
. 
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Implementation of Smartly-Designed Fluorescent Ligand 
Comparison to Ideal Characteristics 
The experimentally determined characteristics of the APTS-MT can then be 
plotted on the 2D sensitivity maps to have an idea of its expected ability to optimize 
these mechanisms.  It is shown as the black X on the recognition map of Figure 57 and 
on the transduction map of Figure 58.  The white x is the 4 kDa FITC-dextran from the 
previous chapter.  This shows that it is expected to show significantly improved results 
when compared to the results from the 4 kDa FITC-dextran.   
 
 
Figure 57: Modeled recognition sensitivity of ConA-based sensor with a fluorescent 
competing ligand at 500 nM.  The white X represents 4 kDa FITC-dextran.  The black X 
represents APTS-MT.   
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Figure 58: Modeled transduction sensitivity (anisotropy). The white X represents 4 kDa 
FITC-dextran.  The black X represents APTS-MT 
 
 
The suitability of the fluorescence lifetime to transduce the binding event can 
also be shown by directly comparing it with a curve from the measured rotational 
correlation lifetimes. The steady-state anisotropy for each rotational correlation lifetime 
was predicted for the full range of possible fluorescence lifetimes.  Figure 59 shows the 
difference between these two curves in the red.  The ideal fluorophore for a specific 
change in rotational correlation lifetimes would display a fluorescence lifetime that 
generates the largest change in the steady-state anisotropies.  The APTS-MT 
fluorescence lifetime of 5.3 ns matches the peak of that curve, making it ideal to 
optimize the transduction mechanism of the fluorescence assay.     
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Figure 59: This shows the expected steady-state anisotropy of the bound (solid) and free 
(dotted) APTS-MT for a range of fluorescence lifetimes.  The difference of the bound 
and free is indicated in red, and the APTS-lifetime is shown with the arrow. 
 
 
Fluorescence Anisotropy Based Assay 
Various Sugars 
Using the results from the modeled assay, the concentrations of the binding assay were 
chosen to be 200 nM APTS-MT and 1 µM unlabeled ConA.  Following a similar 
strategy as the affinity-binding studies between APTS-MT and ConA, microplate wells 
were loaded with this assay with varying concentrations of methyl mannose, glucose, 
and galactose from ~0.2 mg/dL to ~10,000 mg/dL.  The assay was given an appropriate 
time to reach equilibrium at room temperature (22 deg C) and the steady state anisotropy 
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was scanned using the filter-based fluorescence microplate reader.   The results are 
displayed in a semi-log plot in Figure 60 
    
 
Figure 60: Fluorescence anisotropy response of the 200 nM APTS-MT, 1 µM ConA 
assay to methyl mannose, glucose, and galactose 
 
 
The responses in Figure 60 shows that the binding of the APTS-MT to ConA is 
effectively inhibited by monosaccharides that are known to only bind to the primary 
binding of ConA (mannose and glucose).  In addition, methyl mannose is known to have 
a binding affinity that is ~20-40 times higher than glucose.
123
  The concentration that 
causes a 50% reversal of the binding is on that order of increase for glucose.  This is 
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what is expected from the Chung-Prusoff equation for competitive binding.
143
 Lastly, 
galactose has no response on the assay, which is also to be expected.  Galactose shows 
no affinity to ConA, therefore it is not expected to displace the APTS-MT.  This set of 
results is highly encouraging and suggests that the APTS-MT is truly undergoing true 
competitive binding. 
 
Calibration and Prediction of Glucose 
Additional anisotropy experiments were performed with the assay to have more 
measurements in the physiologically relevant glucose concentrations.  The actual 
glucose concentrations were determined on a YSI biochemistry analyzer.  These 
anisotropy values, shown in Figure 61 were used to generate a calibration fit via the 
typical competitive binding equation, and this equation was used to predict the glucose 
concentrations.  The prediction glucose vs. actual glucose (using the same data set) curve 
is shown in Figure 62.  This shows a standard error of calibration of 8.5 mg/dL and a 
mean absolute relative difference (MARD) of 6.5% across physiologically relevant 
glucose concentrations.  In comparison to the prediction vs. actual plot of the assay 
based on the 4 kDa FITC-dextran, the points using the APTS-MT are much closer to the 
central line.  The slight fluctuations are expected to either be pipetting error rather than 
error with the assay.     
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Figure 61: Fluorescence anisotropy response to physiological glucose concentrations 
using a 200 nM APTS-MT, 1 µM ConA solution in TRIS buffer at 22 deg C. 
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Figure 62: Predicted glucose vs. actual glucose for the FA competitive binding assay 
using 200 nM APTS-MT and 1 µM ConA. 
 
 
FRET-Based Glucose Assay 
Even though this optimized anisotropy-based assay transduces the glucose 
concentrations effectively, an assay based on FRET has the potential to increase the 
sensitivity further.  The anisotropy-assay is only as good as the polarizers that are being 
used.  In this case, we are using polarizers with an extinction of 6000:1.  Even with 
improved polarizers, there will be considerable more error in an optimized anisotropy 
assay than an optimized FRET assay.  As a result, a FRET assay was then generated to 
use the smartly-designed fluorescent ligand as the donor.   
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The APTS-MT is expected to be extremely well-suited to translate to a FRET-
based assay because it is the first fluorescent ligand for ConA-based assays that displays 
a fluorophore directly next to the only moiety to which ConA can bind.  Traditional 
ligands paired with ConA (such as 70 kDa dextran) have been 10 nm in diameter and 
have displayed multiple places for ConA to bind.  Upon binding of an acceptor-labeled 
ConA to the multivalent fluorescent ligand, the fluorophore on the fluorescent ligand 
could be various distances to the acceptor fluorophores on ConA.  Because of the 
possible distances between donor and acceptor fluorophores, this can result in a binding 
event that appears to still be in free solution.     
This APTS-MT avoids that fate by bringing the fluorophore to within ~1 nm of 
ConA‟s binding site every time that ConA binds the APTS-MT.  Therefore, with the 
appropriate acceptor fluorophore on ConA and with high enough degree of labeling, the 
expected FRET efficiency upon binding can be very high.  For these experiments, 
TRITC was used as the acceptor fluorophore and was labeled to ConA.  The degree of 
labeling was approximately 4 fluorophores per ConA.  Fluorescence measurements were 
performed on an ISS PC1 spectrofluoremeter.  The concentrations used to obtain the 
excitation/emission spectra for APTS-MT and TRITC-ConA was 100 nM and 1 µM, 
respectively.  This is expected to have a Fӧrster radius similar to FITC/TRITC (~5 nm).  
The excitation and emission properties are shown in Figure 63.  
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Figure 63: The excitation and emission properties of the APTS-MT and the TRITC-
ConA used in the FRET assay.  The shaded area indicates the spectral overlap. 
 
 
A 100 nM APTS-MT solution was then made in TRIS buffer for titration 
experiments.  Increasing TRITC-ConA concentrations were added to the cuvette, and 
fluorescence measurements were taken.  The resulting spectra are shown in Figure 64, 
which display a decrease in the donor fluorescence (APTS-MT) and an increase in the 
acceptor fluorescence (TRITC-ConA).   
 
 137 
 
 
Figure 64: Fluorescence emission from a sample with 100 nM APTS-MT and 
increasing [TRITC-ConA]. 
 
 
The fluorescence intensity at 520 nm (from the APTS-MT) for each TRITC-
ConA concentration was normalized to the fluorescence intensity at 520 nm in the 
absence of TRITC-ConA.  These values were then plotted as a function of the APTS-
ConA concentration and are shown in Figure 65.  This data was fitted with Equation 18 
to account for both of the components that decrease the fluorescence intensity.  This 
includes: (1) the energy transfer associated with binding to the TRITC-ConA and (2) the 
effects that adding the acceptor fluorophore to the bulk solution. This fitting shows that 
the affinity of the APTS-MT and TRITC-ConA binding is 3,522,367 M
-1
, which is 
slightly lower than the affinity obtained from anisotropy measurements with unlabeled 
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ConA.  The fitting also showed that b was equal to 0.1968, which indicates the intensity 
that is expected to be seen if 100% of the APTS-MT was bound.  This value can be used 
as a measure of the average FRET efficiency of the bound population, and suggests that 
the efficiency for this competitive binding pair is ~80.3%.  This confirms that the 
smartly-designed fluorescent ligand can effectively bring the fluorophore to within the 
Fӧrster radius of the FRET pair upon binding.   
 
 
Figure 65: Decrease in fluorescence intensity from APTS-MT as a function of [TRITC-
ConA] and the best fit using Eq. 18.  The Ka of the specific binding is shown. 
 
 
   (     (     ⁄  )   ⁄ )      (18) 
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  The acceptor-peak fluorescence intensity should show a similar affinity; 
however, the tail of the emission from the APTS-MT overlaps with the emission of the 
TRITC-ConA.  Therefore, spectral un-mixing was performed to study the acceptor 
fluorescence.   These unmixed spectra of TRITC-ConA emission are shown in Figure 
66.  The peak of this emission at 585 nm of each of these curves was plotted as a 
function of the TRITC-ConA concentration and shown in Figure 67.  Again, this is fit 
with Equation 18 to account for both of the components that increase (in this case) the 
fluorescence intensity.  This fit shows that the affinity of the APTS-MT and TRITC-
ConA binding is 3,258,390 M
-1
, which agrees well with the information obtained from 
the donor peak.    
 
 
Figure 66: Fluorescence intensity of the TRITC-ConA as a function of increasing 
[TRITC-ConA] after spectral unmixing to remove the APTS-MT emission. 
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Figure 67: Increase in the fluorescence intensity from TRITC-ConA as a function of 
[TRITC-ConA], and the best fit using Eq. 18.  The Ka of the specific binding is shown. 
 
 
A FRET-based competitive assay was then generated that was comprised of 100 
nM APTS-MT and 1 µM TRITC-ConA in TRIS buffer.  This was used to track the 
competitive binding to various sugars with the fluorescence.  Upon titration of highly 
concentrated aliquots of methyl-alpha-mannose and glucose, sufficient was time was 
given to allow for equilibrium to be reached before fluorescence measurements were 
made.  Excitation was performed at 450 nm with a 15 nm bandpass and emission was 
collected from 475 nm to 675 nm to collect both APTS and TRITC‟s emission.  The 
responses are shown in Figure 68.  The blue and red lines show indicate the wavelengths 
(520 nm and 600 nm) that are used to generate the fluorescence ratio (520:600).   
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Figure 68: Fluorescence response to increasing concentrations of methyl mannose and 
glucose in the FRET assay (100 nM APTS-MT and 1 µM TRITC-ConA), showing the 
(A) spectra and (B) ratio on a semilog plot.   
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The resulting spectra show that increasing concentrations of the monosaccharides 
increase the relative fluorescence of the donor-fluorophore, which is characteristic of 
competitive binding.  The acceptor emission appears to increase slightly with increasing 
concentrations of monosaccharides, but this is due to the spectral overlap of the tail of 
the emission of APTS-MT at longer wavelengths.  By taking a ratio of the main peak of 
the donor fluorescence (at 520 nm, blue line) and the tail of the acceptor fluorescence (at 
600 nm, red line), a ratiometric signal was generated.  These ratiometric responses show 
a similar effect to what is seen for the anisotropy-based assay as seen in the semilog plot 
in Figure 68B.  The assay responds to lower concentrations of methyl-mannose than 
glucose, which is to be expected because of ConA‟s higher affinity to methyl-mannose.        
Figure 69 shows the glucose dependent fluorescence ratio on a linear plot with 
the best fit data using the aforementioned curve for competitive binding data.  The r
2
 of 
this fit is 0.9986.  This specific assay shows a linear response across the physiological 
glucose concentrations.  The prediction glucose vs. actual glucose (using the same data 
set) curve is shown in Figure 70.  Again, the error associated with this fit is most likely 
due to pipetting error.  This assay could be tweaked to maximize the response, as the 
effective IC50 for the fit is 792 mg/dL.  The response could also be increased by labeling 
ConA with additional acceptor fluorophores to increase the FRET efficiency upon 
binding to the APTS-MT.   
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Figure 69: Glucose-dependent fluorescence ratio using the FRET-based sensing assay 
with the smartly-designed fluorescent ligand.   
 
 
 144 
 
 
Figure 70:  Predicted glucose vs. actual glucose for the FRET competitive binding assay 
using 100 nM APTS-MT and 1 µM TRITC-ConA. 
 
 
Conclusions 
This chapter introduces a modular approach to the design of a smartly-designed 
fluorescent ligand to achieve the desired qualities as outlined in the previous chapter.  
The core trimannose was identified as a potential high-affinity ligand for ConA due to 
binding of it to the extended binding site of ConA (also known as subsite).  This core 
trimannose showed no aggregation when paired with ConA, and a fluorescent ligand was 
synthesized to present a single trimannose moiety.  This smartly-designed fluorescent 
ligand was characterized and shown to be in the optimized regions of the sensitivity 
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maps as previously defined.  According to those maps, the assay was implemented into 
anisotropy and FRET-based assays for glucose.  These assays showed a dynamic 
response across physiological glucose concentrations – where the error was most likely 
due to pipetting error rather than instrument error.   
The comparison of this first generation smartly-designed fluorescent ligand to 
previously-used high-affinity fluorescent ligands is shown in Table 7.   This ligand is 
expected to remain stable when paired with ConA as it shows a single sugar motif, to 
avoid crosslinking between multivalent components and it is negatively charged to avoid 
electrostatic effects.  Finally, the fluorophore is near the motif to allow for the FRET-
efficiency upon binding to be maximized.  
 
Table 7: Comparison of various ligands with regard to desirable characteristics for a 
ConA-based sensor, including the 1
st
 generation smartly-designed fluorescent ligand 
(APTS-MT) 
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CHAPTER V 
A 2
ND
 GENERATION SMARTLY-DESIGNED FLUORESCENT LIGAND BASED 
ON GLYCATED OVALBUMIN
*
 
 
Introduction 
Requirements for Final Assay 
The previous chapter introduced the smartly-designed fluorescent ligand concept 
to overcome the irreversibility/aggregation problems that have plagued ConA-based 
glucose sensing assays in free solution.  This smartly-designed fluorescent ligand: (1) 
displays a single moiety that can bind to ConA‟s full binding site, (2) is negatively 
charged, and (3) is fluorescently labeled.  An obstacle remains for this strategy to be 
used in a continuous glucose sensor: the size of this smartly-designed fluorescent ligand 
must be increased to prevent leaching from the semi-permeable membrane that allows 
for glucose diffusion.  Figure 71 is a cartoon schematic that shows the relationship of 
various ligands to the pore size of the semi-permeable membrane. 
 
                                                 
*
 Part of this chapter is reprinted from B. M. Cummins, J. Simpson, Z. Gryczynski et al. “ConA-based 
glucose sensing using the long-lifetime Azadioxatriangulenium fluorophore” (2014) with kind permission 
of SPIE, Copyright 2014. 
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Figure 71: Schematic representation of the semi-permeable membrane and the 
molecular sizes that will be required for the smartly-designed fluorescent ligand to 
prevent leaching. 
 
 
Ovalbumin Characteristics 
This chapter introduces ovalbumin (the primary protein in egg-white) as the 
high-affinity fluorescent ligand in a ConA-based glucose sensing assay.  We have 
identified ovalbumin as a possible template for a 2
nd
 generation smartly-designed 
fluorescent ligand as: (1) it has a single glycosylation site that can present a high-
mannose glycan (contains the core trimannose), (2) it is negatively charged at 
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physiological pH (with an isoelectric point of 4.5), (3) it has a molecular weight of 45 
kD, and (4) it has numerous lysine residues that can be labeled with an amine-reactive 
fluorophore.
144
  Table 8 shows the comparison of the expected fluorescent glycated 
ovalbumin in comparison to the fluorescent dextran, fluorescent dendrimer and the 1
st
 
generation smartly-designed fluorescent ligand.  While this strategy does not display the 
fluoroophore near the sugar motif, this strategy was can possibly be used as a cost-
effective method to generate the bulked-up, 2
nd
-generation, smartly-designed fluorescent 
ligand without a significant number of synthetic steps.    
 
Table 8: Comparison of various ligands with regard to desirable characteristics for a 
ConA-based sensor, including the proposed 2
nd
 generation smartly-designed fluorescent 
ligand based on ovalbumin. 
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Aadioxatriangulenium (ADOTA) Fluorophore 
This preliminary study uses the Azadioxatriangulenium (ADOTA
+
) fluorophore 
as ADOTA
+
 has fluorescence properties ideal for tracking the binding between 
ovalbumin and ConA.
145-147
 ADOTA
+
 displays excitation and emission maxima at 540 
nm/560 nm with a fluorescence lifetime of ~23 ns.  It has moderate brightness with a 
molar extinction coefficient of 9,800 cm
-1
M
-1
 and a quantum yield of 0.49 (determined 
in acetonitrile), with an intrinsic anisotropy has been shown to be 0.38.
148,149
  The 
structure of ADOTA-NHS is shown in Figure 72.  With these fluorescence properties, 
ADOTA
+ 
can allow binding studies between relatively large molecules to be tracked 
with anisotropy,
150
 and it can be used to avoid the shorter fluorescence lifetimes that are 
common for endogenous fluorophores.
151
   
 
 
Figure 72: Structure of ADOTA-NHS  
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Preparation of ADOTA-Labeled Glycated Ovalbumin 
The ConA-based assay, as we present it, tracks the fluorescence intensity from 
the fluorescently-labeled ovalbumin.  As a result, it is essential that all of the ovalbumin 
can bind to ConA.  If a portion of the fluorescently labeled ovalbumin cannot bind to 
ConA, it will serve as a background signal that is not sensitive to glucose concentration 
and will increase the error of the sensor.  The glycans on proteins can display a 
significant amount of variation, and a large fraction of proteins that can be glycated do 
not actually display glycans.  A schematic of the preparation of the ADOTA-labeled 
glycated ovalbumin (ADOTA-OVA) and how it will be implemented in the assay is 
shown in Figure 73.   
 
 
Figure 73: Top: Schematic of the preparation of ADOTA-OVA from native 
ovalbuminm, including (A) affinity chromatography and (B) fluorescent labeling. 
Bottom:  Schematic glucose response of the ConA-based assay with the ADOTA-OVA 
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Affinity Chromatography 
We separated the glycated fraction from the non-glycated fraction of our 
ovalbumin sample by performing affinity-chromatography with ConA-functionalized 
resin.  The protein elution from the column was tracked by monitoring the absorbance at 
280 nm.  After the non-glycated fraction eluted from the column, high concentrations of 
mannose were used to elute the glycated fraction.  This glycated fraction was collected 
and dialyzed in sodium bicarbonate buffer to prepare it for labeling.  The elution profile 
of the affinity chromatography is shown in Figure 74. 
 
 
Figure 74: Affinity chromatography of the native ovalbumin sample to separate the non-
glycated fraction (1
st
 peak) from the glycated fraction (2
nd
 peak).  
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Fluorescent Labeling of Ovalbumin 
This glycated fraction of the ovalbumin was labeled with the ADOTA-NHS 
according to traditional amine-reactive protocol.  Briefly, ADOTA-NHS was dissolved 
in DMSO, added dropwise to the solution of glycated ovalbumin in sodium bicarbonate 
buffer (pH 9 to deprotonate the primary amines), mixed well, and allowed to react for 1 
hour in the dark at room temperature.  Afterwards, the free dye was removed via dialysis 
against TRIS buffer, and the solution was filtered with syringe filters.  In other samples, 
the free dye was removed via size exclusion chromatography (SEC) with the HPLC 
pump system.  For both the SEC and syringe filter step, it was clear that a significant 
amount of fluorescent material was getting stuck in the matrices.  Because this solution 
should not be capable of labeling the Sephadex media or the cellulose membranes, this 
could indicate that the ADOTA-OVA aggregated with itself.  Unfortunately, if ADOTA-
OVA aggregates with itself, this would present multiple glycans on the surface of a 
single complex and decrease the effectiveness of the ovalbumin to serve as a smartly-
designed fluorescent ligand.  Nevertheless, this ADOTA-OVA was tested 
experimentally to determine its ability to be used in a glucose sensor.  If it truly is 
aggregating, there are potential methods to decrease these non-specific interactions. 
To determine the concentrations and degree of fluorescent labeling, UV/VIS 
absorbance measurements were performed in TRIS buffer.  Using the molar extinction 
coefficients, the concentration and degree of labeling of the ADOTA-OVA was 
determined.  Similar UV/VIS studies were performed with the AF647-ConA that was 
purchased from Invitrogen.  The degree of labeling of the ADOTA-OVA was 
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determined to be approximately 1.5 ADOTA fluorophores per glycated ovalbumin.  The 
degree of labeling of the AF647-ConA was determined to be approximately 3 AF 647 
fluorophores per ConA.    
An expected 3D representation of the ADOTA-glycated ovalbumin was 
developed by using the x-ray crystallography structure of ovalbumin found published 
(PDB: 3VVJ) and altering it in the Maestro software.  To the asparagine residue (Asp-
292), a high mannose glycan was attached.  Two ADOTA fluorophores were attached to 
two of the primary amines coming from the lysine groups.  This representation is shown 
in Figure 75. 
 
 
Figure 75: Expected structure of the ADOTA-glycated ovalbumin as modified from the 
crystallography structure for ovalbumin (blue) (3VVJ) with the glycan (green) and 
ADOTA (yellow).   
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Fluorescence Anisotropy with ADOTA-OVA 
Figure 76 shows the 2D sensitivity map for the anisotropy transduction 
mechanism as previously defined.  Fluorescence anisotropy is typically limited to 
tracking small fluorescent ligands to large receptors.  Since ovalbumin is relatively large 
in size (~45 kDa), most organic fluorophores would not show a change in anisotropy 
upon binding as they typically display a fluorescence lifetime of a few ns.  ADOTA can 
allow the equilibrium binding of ovalbumin and ConA to be tracked with fluorescence 
anisotropy because of its longer fluorescence lifetime (~20 ns).  The white dot displays 
the expected location of ADOTA-OVA on this map of the transduction sensitivity. 
   
 
Figure 76: The fluorescence anisotropy sensitivity as a function of MW and lifetime.  
The white dot represents ADOTA-OVA. 
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Being able to track the ovalbumin-ConA interactions with anisotropy, allows the 
association constant to be determined in a realistic environment.  This association 
constant can then be confidently used in the competitive binding model to generate an 
optimized assay for the desired glucose concentration range.  The fluorescence 
anisotropy of a 500 nM solution of ADOTA-glycated ovalbumin was tracked as a 
function of ConA concentration using a Fluorolog 3 spectrofluorometer and is shown in 
Figure 77.  This data was fit with a Boltzmann curve, and the affinity was determined to 
be 587,000 M
-1
.  This anisotropy could be used as a glucose-sensor like in the previous 
chapter; however, the limited change in anisotropy for this competitive binding pair is 
expected to have problems with glucose prediction.  
 
 
Figure 77: Fluorescence anisotropy response of 500 nM ADOTA-OVA to increasing 
[ConA].  The Ka was determined to be 587,000 M
-1
. 
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FRET-Based Studies with ADOTA-OVA 
The eventual goal for the ADOTA-OVA is to be paired with ConA behind a 
semi-permeable membrane to create a fluorescent sensor that can track glucose 
concentrations in vivo.  As a result, it is essential for this assay to function as a FRET-
based assay.  To track the competitive binding with energy transfer, an acceptor 
fluorophore was added to ConA.  For this work, AF647 was chosen as a suitable dye to 
allow for spectral overlap while minimizing the direct excitation of the acceptor 
fluorophore.  Figure 78 shows a schematic of the energy transfer from the ADOTA-
OVA to the AF647- ConA.   
 
 
Figure 78: Schematic of the energy transfer upon binding of the ADOTA-OVA (light 
gray) to the AF647-ConA (dark gray tetramer) via the single N-linked glycan (green) 
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Figure 79: Molecular representation of the expected binding of ADOTA-OVA to the 
AF647-ConA. 
 
 
The 3D representation of the interaction between the ADOTA-glycated 
ovalbumin and AF647-ConA was done in a similar way with the Maestro software.  This 
representation is shown in Figure 79.  This can help one see the types of distances that 
are between the donor and acceptor fluorophores upon binding of a portion of the high-
mannose glycan to the full binding site of ConA.  The steady-state excitation and 
emission spectra for ADOTA and AF647 are shown in Figure 80. 
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Figure 80: Excitation/Emission spectra of ADOTA
+
 and AF 647 in TRIS.  The dashed 
horizontal line -indicates the spectral overlap which is required for energy transfer. 
 
 
Stopped Flow Measurements 
The stopped-flow technique is one that mixes two solutions together very quickly 
to allow for the kinetics of a solution to be monitored over time.  This can be useful to 
study receptor-ligand interactions of a fluorescence-based assay that is engineered to 
change its fluorescence properties upon binding.  For such an assay, the receptor is 
loaded into one syringe and the ligand is loaded into the other syringe.  The solutions are 
driven to the mixing chamber which occurs in a cuvette.  If this cuvette is placed in a 
typical spectrofluorometer, the fluorescence intensity can be tracked as a function of 
time.  It is also possible to monitor anisotropy as a function of time, but this 
measurement requires the spectrofluorometer to be in a T-format configuration with two 
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emission pathways where one collects perpendicular fluorescence and the other collects 
parallel. 
Using our FRET-based assay with ADOTA-OVA and AF647-ConA, the 
intensity of the ADOTA-OVA is expected to decrease upon binding to AF647-ConA.  It 
is important to note, that the concentration of interest is the final concentration.  These 
studies used identical syringes for the receptor and ligand.  So, the concentrations in the 
cuvette were half of what was loaded into the syringes.  Originally, the ADOTA-OVA 
was loaded at concentration of 1 µM.  Three different ConA concentrations were loaded 
into the receptor chamber (0.33 µM ConA, 0.66 µM ConA, and 2 µM ConA).  The 
trigger from the stopped-flow accessory was an input to the software to begin 
fluorescence collection.  The excitation was set to 500 nm, and the emission was set to 
550 nm to measure the emission peak from the ADOTA-OVA.  The fluorescence 
intensity was measured every 0.1 second for 100 seconds.   
These time-dependent fluorescence decays can then be normalized to the initial 
fluorescence intensity.  The initial intensity decreases due to two primary reasons – 
neither of which is due to binding events.  Because the AF647 can be directly excited by 
the excitation light, the increasing concentrations of the AF647 cause a decrease in the 
excitation light that actually gets to the ADOTA fluorophore.  In addition, because of the 
spectral overlap of the ADOTA emission and AF 647 excitation, there exists the 
possibility of the ADOTA-emission being reabsorbed by AF647.  While it‟s also 
possible that diffusion-dependent energy transfer could occur, the concentrations are not 
high enough to make this occur on the time-scale that ADOTA is in the excited state.  
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After normalizing the fluorescence decays to the initial fluorescence, they can be fit with 
a single exponential decay.  This is shown in Figure 81. 
 
 
Figure 81: Stopped flow measurements of 500 nM ADOTA-OVA as a function of 
[AF647-ConA] in TRIS buffer at 22 deg C and the exponential decay constants. 
 
 
The traditional practice for stopped flow measurements is to plot these apparent 
rate constants as a function of the receptor concentration like in Figure 82.
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  The best 
fit line to this data generates the expected kon and koff rates.  The kon rate is the slope of 
that line and the koff rate is the y-intercept at low ovalbumin concentrations.  These 
results show that the association constant (equivalent to kon/koff) is approximately 
554,000 M
-1 
which is very similar to the previous results that were determined with 
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anisotropy.  By knowing the kinetic rate constants, the time-dependent competitive 
binding can be determined using numerical methods.   
 
 
Figure 82: The exponential decay constants vs. [AF647-ConA] which can be used to get 
the kinetic rate constants of ADOTA-OVA to ConA from the slope and y-intercept. 
 
 
Steady-State FRET Based Glucose Assay 
To test the steady-state glucose response, the assay was chosen to have 500 nM 
ADOTA-OVA and 1 µM AF647-ConA.  This assay was loaded into a cuvette of TRIS 
buffer, and highly concentrated glucose aliquots were added to minimize dilution effects.  
Upon each addition, the solutions were mixed well and given time to equilibrate.  At 
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each glucose concentration (0 mg/dL-500 mg/dL)), the steady-state fluorescence was 
measured on a Fluorolog 3.  Excitation was at 500 nm with a 10 nm bandwidth.  
Emission was collected from 530 nm to 750 nm with a 5 nm bandwidth.   
The assay displayed glucose-dependent fluorescence spectra that are 
characteristic of competitive binding (Figure 83).  The fluorescence of the ADOTA-
OVA increased with increasing concentration, indicating that the concentration of 
ADOTA-OVA undergoing FRET (bound population) was decreasing.  The emission of 
each fluorophore is sufficiently separated to minimize the effect that the changing 
fluorescence intensity of ADOTA has on the AF 647 fluorescence.  The ratio of the 
donor to acceptor maxima (560 nm to 670 nm) as a function of glucose concentration is 
also shown.  This shows that the fluorescence of this ADOTA-OVA and AF 647 ConA 
assay primarily changes from 0-300 mg/dL, and then begins to flatten out.   
 
 
Figure 83: Glucose response of the fluorescence assay comprised of 500 nM ADOTA-
OVA and 1 µM AF647-ConA. 
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By using the ovalbumin as the fluorescent ligand, it reverts back to one of the 
problems that the traditional ligands (i.e. dextran) displayed.  The molecule itself is large 
enough to allow a large percentage of the bound population to display a low FRET 
efficiency with the acceptors on the ConA.  That said, this assay still shows a significant 
increase across physiological glucose concentrations (~30% fluorescence increase), and 
it could potentially be increased further by increasing the AF647-ConA concentrations 
further.  This could also be increased by site-specific labeling of the N-terminus of the 
ovalbumin.  In the crystal structure, the N-terminus appears to be fairly close to where 
the high-mannose glycan resides and could allow for improved FRET efficiency.  Figure 
84 shows the 2D sensitivity map, and plots where an assay based on 1 µM ConA would 
be expected to reside (white arrow).  By increasing the concentration of the AF647-
ConA, this fluorescence response is expected to increase further.   
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Figure 84: 2D plot of sensitivity of recognition scheme with the assay from Figure 83 
(white line) and where it could be to increase the sensitivity (black line) 
 
 
FRET-based Glucose Assay with Fluorescence Lifetimes  
An assay was generated using 500 nM ADOTA-OVA and 4 µM AF647-ConA 
for FRET-based studies where the fluorescence lifetime decays were analyzed instead of 
the steady-state intensity.  The fluorescence lifetime was collected using a DeltaFlex 
time correlated single photon counting system from Horiba that was equipped with a 482 
nm DeltaDiode pulsed source.  The emission was set to 540 nm with the slit-width 
allowing 8 nm bandpass.  A high-pass filter of 500 nm was used to block scattered 
excitation light.  The excitation polarizer was in the vertical orientation and the emission 
polarizer was set to the magic angle.  Data was taken until the maximum counts were 
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1,000.  Silica particles in DI were used as the sample to scatter light to determine the 
pulse-shape of the 482 nm source.  The fluorescence decays of the 500 nM ADOTA-
OVA and the assay of the 500 nM ADOTA-OVA with 4 µM AF647-ConA are shown in 
Figure 85.   
 
 
Figure 85: Time-dependent fluorescence decay of (a) 500 nM ADOTA-OVA and (b) 
500 nM ADOTA-OVA with 4 µM AF 647 ConA in TRIS buffer at 22 deg C. 
 
 
The time-dependent fluorescence decays were fit with three exponentials.  Two 
of these lifetimes were fixed: one for the shorter lifetime at 2.07 ns and the other for the 
longer lifetime at 18.19 ns.  A third lifetime (on the order of picoseconds) was also 
implemented in the fit to account for the scatter that was seen in the experiments.  The 
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full decay of each solution was fit using with this equation by minimizing the residuals. 
The weighted intensities at time zero of the short and long lifetime decays (B1 and B2) 
were then recorded as a function of glucose concentration.  These values are expected to 
be a function of the equilibrium binding between ADOTA-OVA and AF647-ConA.  The 
population that is capable of undergoing FRET is expected to primarily display the 
shorter lifetime.  The population that does not undergo FRET is expected to primarily 
display the longer lifetime.  Therefore B2/(B1+B2) should correlate to how much of the 
ADOTA-OVA is free.  The glucose-dependent response to this value is shown in Figure 
86.  The competitive binding equation was again used to fit this data, and a best fit was 
generated with am IC50 of 386.9 mg/dL.  The prediction glucose vs. actual glucose 
(using the same data set) curve is shown in Figure 87.  The standard error of calibration 
was 8.25 mg/dL, and the calibration MARD was 4.19%. 
Improvements could potentially be made on the assay by increasing the degree of 
labeling on ConA or performing site-specific labeling on the ovalbumin with the 
ADOTA
+
 fluorophore.  Both of these strategies could improve the average FRET 
efficiency of the bound ovalbumin population.   
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Figure 86: Glucose-dependent ratio of the long-lifetime component of an assay 
comprised of 500 nM ADOTA-OVA and 4 µM AF 647 ConA. 
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Figure 87:  Predicted glucose vs. actual glucose for the FRET competitive binding assay 
using 500 nM ADOTA-OVA and 4 µM AF647-ConA tracking fluorescence lifetimes. 
 
 
Conclusions 
This work introduces the naturally-occurring ovalbumin as the core-component 
of a 2
nd
 generation smartly-designed fluorescent ligand to be paired with ConA in a 
fluorescence glucose sensor.  The glycated fraction of ovalbumin was separated with 
affinity chromatography and labeled with the long-fluorescence-lifetime ADOTA
+
 dye 
to allow the binding to be tracked via fluorescence.   A FRET assay was generated by 
pairing ADOTA-OVA with AF647-ConA that showed a fluorescence response across 
physiologically relevant glucose concentrations.  This could be tracked by looking at the 
changes in fluorescence lifetime of the ADOTA fluorophore and the steady-state 
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fluorescence intensity.  This preliminary work indicates that the ADOTA-OVA 
fluorescent ligand could potentially allow the translation of the smartly-designed 
fluorescent ligand concept into a continuous glucose monitoring device 
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CHAPTER VI 
SUMMARY AND FUTURE WORK 
 
In summary, the goal of this research was to engineer a homogeneous ConA-
based competitive binding assay that could remain stable in free solution and predict the 
glucose concentration of that solution from the fluorescence signal of the assay.   
The initial work used glycosylated dendrimers as the competing ligand.  
Different versions of the glycosylated dendrimer were tested in an attempt to identify a 
specific version that enabled the assay to most-effectively track physiological glucose 
concentrations.  These versions varied in size, number of sugar residues, type of surface 
chemistry, number of charges on the surface, and the fluorophore that was used.  Assays 
were generated with a range of dendrimer and ConA concentrations and examined for 
the change in fluorescence properties across physiological glucose range.  One version 
of this assay was encapsulated via the microporated microsphere approach and the 
response of these sensors was tested with physiological glucose concentrations.  These 
sensors displayed some reversibility over time; however, the extent of their fluorescent 
response changed.  The assays that used this type of glycosylated dendrimer continued to 
display problems with stability and reversibility in free solution and it showed several 
inconsistencies that were later attributed to electrostatic interactions and aggregation.  
The problems with this approach resulted in the desire to explore alternative assay 
configurations.   
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Mathematical modeling was then performed to identify the characteristics of an 
assay that could allow for dynamic fluorescence changes to physiological glucose 
concentrations.  This work separated the recognition and transduction mechanisms of a 
fluorescent competitive binding sensor, and each mechanism was modeled 
independently.  The transduction mechanism was chosen to be fluorescence anisotropy 
to make the system simpler and allow it to be linear.  The sensitivity of the measured 
anisotropy is then the convolution of the sensitivities of each mechanism, making it 
necessary for both to respond accordingly.  For the transduction mechanism, the steady-
state anisotropy was modeled for fluorescent competing ligands of different molecular 
weight and fluorescent lifetimes.  The expected steady-state anisotropy was modeled for 
the free-state and the bound-state (to tetrameric ConA) for each ligand, assuming each 
version was a perfect sphere at the molecular weight of the complex.  For the recognition 
mechanism, an exact solution to the competitive binding equation was used for a set of 
affinities and concentrations.  From these models, 2D sensitivity plots were generated 
for each mechanism to identify optimal assay configurations, and a combined model was 
made to predict the change in anisotropy for various assays. 
The combined model was then validated by testing the glucose response of 
assays that paired 4 kDa FITC-dextran with different concentrations of ConA.  After 
predicting the correct trends, this model was used to explain the previous problems 
associated with ConA-based glucose sensing assays in free solution. From this 
explanation, we postulate the hypothesis that the full potential of ConA-based assays can 
be shown if a fluorescent competing ligand is employed that achieves the high-affinity 
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required without allowing for aggregation to occur with ConA.  In addition, we 
identified ideal characteristics to maximize both the recognition and transduction 
mechanism.   
We overcome the apparent dilemma between sensitivity and aggregation by 
identifying an alternative method to achieve the increased affinities.  Instead of using 
proximity effects that requires a multivalent presentation of monosacccharides, we 
employed the use of ConA‟s extended binding site.  The core trimannose is shown to 
form additional hydrogen bonds to the extended binding site while binding to the same 
primary binding site.  A smartly-designed fluorescent ligand was designed and 
synthesized to achieve the desirable characteristics as previously identified without 
allowing for aggregation to occur.  A single presentation of the core trimannose showed 
no aggregation when paired with ConA, unlike dextrans and dendrimers.   
A fluorophore (APTS) was attached to the reducing terminus of mannotetraose 
via reductive amination to generate fluorescent ligand that presented a single core 
trimannose.  This first generation smartly-designed fluorescent ligand was fully tested to 
determine its fluorescent properties (intensity, intrinsic anisotropy, lifetime) as well as its 
binding affinity to ConA.  Then, this smartly-designed fluorescent ligand was paired 
with ConA in a fluorescence anisotropy based glucose sensor.  Afterwards it was paired 
with fluorescently labeled ConA in a FRET assay.  The responses to several sugars are 
shown, displaying that glucose and mannose concentrations can directly compete for 
binding sites on ConA with the smartly-designed fluorescent ligand.  This smartly-
designed fluorescent ligand (1) presented a single core trimannose moiety, (2) was 
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negatively charged, and (3) held the fluorophore close to the trimannose moiety.  This 
approach can allow the assay to remain stable over time, suggesting that this strategy 
could truly show the full potential of ConA-based assays.  However, for this smartly-
designed ligand concept to be translated into a prototype device, the molecular weight 
must be increased to prevent leaching from the semi-permeable membrane. 
In an attempt to generate a low-cost bulked-up ligand that can allow the smartly-
designed fluorescent ligand concept to be translated into a prototype device, various 
glycoproteins were explored.   Ovalbumin – the primary protein found in egg-white - 
was been identified as a possible template for a 2
nd
 generation smartly-designed 
fluorescent ligand as: (1) it has a single glycosylation site that can present a high-
mannose glycan (contains the core trimannose), (2) it is negatively charged at 
physiological pH (with an isoelectric point of 4.5), (3) it has a molecular weight of 45 
kDa, and (4) it has numerous lysine residues that can be labeled with an amine-reactive 
fluorophore.  Affinity chromatography was used to collect only the glycated fraction, 
and this fraction was labeled with a red-emitting, long-lifetime fluorophore (ADOTA) to 
track the binding.  Anisotropy studies were performed with unlabeled ConA and energy 
transfer studies paired the ADOTA-glycated ovalbumin with AF647- ConA.  Many of 
these studies showed very promising glucose-sensing results.  However, the ovalbumin 
seems to be aggregating with itself in a buffer that mimics the interstitial fluid in the 
absence of ConA.  If this is true, a single complex would present multiple trimannose 
groups.  Such a complex would be similar to the multivalent ligands that cause problems 
with stability and repeatability.    
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Future work involves creating stable, bulked up versions of the smartly-designed 
fluorescent ligand.  This could either be done by stabilizing the ovalbumin approach 
through a process like PEGylation or by generating a purely synthetic ligand.  In 
addition, fluorophores could be chosen that excite/emit further into the red, to minimize 
the background from endogenous auto-fluorescence.   Such an assay could be 
encapsulated within the desired matrix and has the potential to remain stable for long 
periods of time if it were paired with stabilized versions of ConA that are currently being 
pursued in the Optical Biosensing Lab,.  
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